<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">sHdhBWFVYYKJCBV7qz6ZWKD</article-id>
      <article-id pub-id-type="other">00004</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011001100004</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09700204</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000073</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Compara&#231;&#227;o entre a ecocardiografia 2D e 3D na avalia&#231;&#227;o do remodelamento reverso ap&#243;s a TRC</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hotta</surname>
            <given-names>Viviane Tiemi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martinelli Filho</surname>
            <given-names>Martino</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mady</surname>
            <given-names>Charles</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mathias Jr.</surname>
            <given-names>Wilson</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vieira</surname>
            <given-names>Marcelo L.C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Fleury Medicina e Sa&#250;de</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Hospital Israelita Albert Einstein</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>08</month>
        <year>2011</year>
      </pub-date>
      <volume>97</volume>
      <issue>2</issue>
      <fpage>111</fpage>
      <lpage>121</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>09</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>08</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>01</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A ecocardiografia consiste em m&#233;todo muito &#250;til para sele&#231;&#227;o e avalia&#231;&#227;o de resposta &#224; terapia de ressincroniza&#231;&#227;o card&#237;aca (TRC). O eco 3D j&#225; tem seu papel estabelecido na avalia&#231;&#227;o dos volumes ventriculares e fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (FEVE) com excelente correla&#231;&#227;o de resultados quando comparado &#224; RNM. OBJETIVO: Comparar a avalia&#231;&#227;o dos volumes ventriculares (VDVE, VSVE), FEVE e massa do VE antes e ap&#243;s a TRC pela ecocardiografia bi (Eco 2D) e tridimensional (Eco 3D). M&#201;TODOS: Foram avaliados 24 pacientes com IC CFIII ou IV (NYHA), ritmo sinusal QRS &gt; 150 ms, em vig&#234;ncia de terap&#234;utica otimizada para IC submetidos a TRC. Foram realizados eletrocardiograma (ECG), avalia&#231;&#227;o cl&#237;nica, Eco 2D e 3D antes, tr&#234;s e seis meses ap&#243;s a TRC. A compara&#231;&#227;o entre as t&#233;cnicas foi realizada utilizando-se a correla&#231;&#227;o de Pearson (r). RESULTADOS: No momento basal, a correla&#231;&#227;o entre os m&#233;todos foi de 0,96 para avalia&#231;&#227;o do VDVE, 0,95 para avalia&#231;&#227;o do VSVE, 0,87 para FEVE, e 0,72 para massa do VE. Ap&#243;s tr&#234;s meses da TRC, a correla&#231;&#227;o entre os m&#233;todos para an&#225;lise do VDVE foi de 0,96, 0,95 para VSVE, 0,95 para FEVE, e 0,77 para massa do VE. Ap&#243;s seis meses da TRC, a correla&#231;&#227;o entre o Eco 2D e 3D para an&#225;lise do VDVE foi de 0,98, 0,91 para VSVE, 0,96 para FEVE, e 0,85 para massa do VE. CONCLUS&#195;O: Neste estudo foi observada redu&#231;&#227;o dos VDVE,VSVE, al&#233;m de melhora da FEVE ap&#243;s a TRC. Houve excelente correla&#231;&#227;o entre o Eco 2D e o 3D para avalia&#231;&#227;o dos volumes ventriculares e FEVE, e boa correla&#231;&#227;o entre os m&#233;todos para avalia&#231;&#227;o da massa ventricular esquerda antes e ap&#243;s a TRC.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Ecocardiografia</kwd>
        <kwd>ecocardiografia tridimensional</kwd>
        <kwd>volume sist&#243;lico</kwd>
        <kwd>dsifun&#231;&#227;o ventricular esquerda</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>17</day>
        <month>06</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Compara&#231;&#227;o entre a ecocardiografia 2D e 3D na avalia&#231;&#227;o do remodelamento reverso ap&#243;s a TRC</bold>
    </p>
    <p>
      <bold>Viviane Tiemi Hotta; Martino Martinelli Filho; Charles Mady; Wilson Mathias Jr.; Marcelo L.C. Vieira</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o (InCor) da Faculdade de Medicina da Universidade de S&#227;o Paulo, Fleury Medicina e Sa&#250;de, Hospital Israelita Albert Einstein, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="ab1">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A ecocardiografia consiste em m&#233;todo muito &#250;til para sele&#231;&#227;o e avalia&#231;&#227;o de resposta &#224; terapia de ressincroniza&#231;&#227;o card&#237;aca (TRC). O eco 3D j&#225; tem seu papel estabelecido na avalia&#231;&#227;o dos volumes ventriculares e fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (FEVE) com excelente correla&#231;&#227;o de resultados quando comparado &#224; RNM. </p>
    <p><bold>OBJETIVO:</bold> Comparar a avalia&#231;&#227;o dos volumes ventriculares (VDVE, VSVE), FEVE e massa do VE antes e ap&#243;s a TRC pela ecocardiografia bi (Eco 2D) e tridimensional (Eco 3D). </p>
    <p><bold>M&#201;TODOS:</bold> Foram avaliados 24 pacientes com IC CFIII ou IV (NYHA), ritmo sinusal QRS <underline>&gt;</underline> 150 ms, em vig&#234;ncia de terap&#234;utica otimizada para IC submetidos a TRC. Foram realizados eletrocardiograma (ECG), avalia&#231;&#227;o cl&#237;nica, Eco 2D e 3D antes, tr&#234;s e seis meses ap&#243;s a TRC. A compara&#231;&#227;o entre as t&#233;cnicas foi realizada utilizando-se a correla&#231;&#227;o de Pearson (r). </p>
    <p><bold>RESULTADOS:</bold> No momento basal, a correla&#231;&#227;o entre os m&#233;todos foi de 0,96 para avalia&#231;&#227;o do VDVE, 0,95 para avalia&#231;&#227;o do VSVE, 0,87 para FEVE, e 0,72 para massa do VE. Ap&#243;s tr&#234;s meses da TRC, a correla&#231;&#227;o entre os m&#233;todos para an&#225;lise do VDVE foi de 0,96, 0,95 para VSVE, 0,95 para FEVE, e 0,77 para massa do VE. Ap&#243;s seis meses da TRC, a correla&#231;&#227;o entre o Eco 2D e 3D para an&#225;lise do VDVE foi de 0,98, 0,91 para VSVE, 0,96 para FEVE, e 0,85 para massa do VE. </p>
    <p><bold>CONCLUS&#195;O:</bold> Neste estudo foi observada redu&#231;&#227;o dos VDVE,VSVE, al&#233;m de melhora da FEVE ap&#243;s a TRC. Houve excelente correla&#231;&#227;o entre o Eco 2D e o 3D para avalia&#231;&#227;o dos volumes ventriculares e FEVE, e boa correla&#231;&#227;o entre os m&#233;todos para avalia&#231;&#227;o da massa ventricular esquerda antes e ap&#243;s a TRC.</p>
    <p><bold>Palavras-chave:</bold> Ecocardiografia, ecocardiografia tridimensional, volume sist&#243;lico, dsifun&#231;&#227;o ventricular esquerda.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A ecocardiografia consiste em m&#233;todo muito &#250;til para sele&#231;&#227;o e avalia&#231;&#227;o de resposta &#224; terapia de ressincroniza&#231;&#227;o card&#237;aca (TRC) para pacientes com insufici&#234;ncia card&#237;aca (IC) grave e dist&#250;rbio da condu&#231;&#227;o ventricular<sup>1-4</sup>. O ecocardiograma tridimensional (Eco 3D) j&#225; tem seu papel estabelecido na avalia&#231;&#227;o dos volumes ventriculares e fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (FEVE) com excelente correla&#231;&#227;o de resultados quando comparado &#224; resson&#226;ncia magn&#233;tica card&#237;aca<sup>5,6</sup>. Em rela&#231;&#227;o ao ecocardiograma bidimensional (Eco 2D), o Eco 3D apresenta maior proximidade &#224; anatomia real em raz&#227;o da aus&#234;ncia de infer&#234;ncias geom&#233;tricas.</p>
    <p>Uma vez que o Eco 2D tem maior disponibilidade e tem sido o m&#233;todo mais utilizado para o acompanhamento desses pacientes, demonstramos nesse estudo sua correla&#231;&#227;o com o Eco 3D na avalia&#231;&#227;o dos volumes ventriculares (volume diast&#243;lico final do ventr&#237;culo esquerdo e volume sist&#243;lico final do ventr&#237;culo esquerdo), fra&#231;&#227;o de eje&#231;&#227;o e massa ventricular esquerda antes e ap&#243;s a TRC.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Foi realizado estudo prospectivo e observacional, no per&#237;odo de 1&#186;.1.2007 a 1&#186;.6.2009. O projeto foi aprovado pela Comiss&#227;o Cient&#237;fica e de &#201;tica do InCor - HCFMUSP, pela Comiss&#227;o de &#201;tica para a An&#225;lise de Projetos de Pesquisa (CAPPesq), da Diretoria Cl&#237;nica do Hospital das Cl&#237;nicas da Universidade de S&#227;o Paulo. Este estudo apresenta os resultados parciais de tese de doutorado, realizada no per&#237;odo descrito, baseando-se em uma amostra de conveni&#234;ncia.</p>
    <p>Foram estudados pacientes com diagn&#243;stico de miocardiopatia de etiologia n&#227;o isqu&#234;mica que preenchessem os seguintes crit&#233;rios:</p>
    <disp-quote>
      <p>1. Idade entre 18 e 75 anos;</p>
      <p>2. Tratamento medicamentoso otimizado na dose m&#225;xima tolerada pelo paciente por pelo menos um m&#234;s antes da inclus&#227;o no estudo;</p>
      <p>3. Ritmo sinusal;</p>
      <p>4. QRS &gt; 120 ms ao ECG de 12 deriva&#231;&#245;es;</p>
      <p>5. FEVE &lt; 0,35 (medida ao ecocardiograma bidimensional pelo m&#233;todo de Simpson);</p>
      <p>6. Di&#226;metro diast&#243;lico final do ventr&#237;culo esquerdo (DDVE) &gt; 55 mm;</p>
      <p>7. Presen&#231;a de sinais e sintomas de IC CF III ou IV (NYHA).</p>
    </disp-quote>
    <p>Os pacientes com idade maior que 40 anos e fatores de risco para doen&#231;a arterial coronariana foram submetidos &#224; realiza&#231;&#227;o de cineangiocoronariografia para exclus&#227;o de etiologia isqu&#234;mica.</p>
    <p>Foram considerados crit&#233;rios de exclus&#227;o: 1) Imagem ecocardiogr&#225;fica inadequada &#224; an&#225;lise tridimensional; o bloco do exame tridimensional foi considerado inadequado para a an&#225;lise quando dois ou mais segmentos n&#227;o foram visibilizados; 2) presen&#231;a de artefatos de transla&#231;&#227;o card&#237;aca; 3) fibrila&#231;&#227;o atrial ou de grande irregularidade do ritmo card&#237;aco pr&#233;-TRC; 4) pacientes impossibilitados de permanecer em pequeno per&#237;odo de apneia (15 a 20 segundos) para aquisi&#231;&#227;o das imagens ecocardiogr&#225;ficas tridimensionais; 5) morte antes de completar pelo menos a primeira reavalia&#231;&#227;o (aos tr&#234;s meses ap&#243;s TRC).</p>
    <p>Os pacientes que preencheram os crit&#233;rios de inclus&#227;o foram encaminhados ao implante de marca-passo atriobiventricular (MPaBiv). Antes da alta hospitalar, os pacientes foram submetidos a avalia&#231;&#227;o ecocardiogr&#225;fica, para programa&#231;&#227;o do intervalo atrioventricular (IAV) &#243;timo, por meio da f&#243;rmula de Ritter<sup>7,8</sup>.</p>
    <p>Ap&#243;s a alta hospitalar, a programa&#231;&#227;o eletr&#244;nica do MPaBiv foi reavaliada no d&#233;cimo dia ap&#243;s implante do marca-passo e, ap&#243;s um e, tamb&#233;m, tr&#234;s meses do implante, de acordo com a rotina da Unidade Cl&#237;nica de Arritmia e Estimula&#231;&#227;o Card&#237;aca Artificial do InCor. O objetivo dessas avalia&#231;&#245;es foi garantir o funcionamento adequado dos MPaBiv, em cada paciente.</p>
    <p>Foram realizados ECG, avalia&#231;&#227;o cl&#237;nica, ecocardiograma bidimensional (2D), e tridimensional (3D) antes, tr&#234;s e seis meses ap&#243;s a TRC. Foram avaliados os seguintes par&#226;metros: volumes do ventr&#237;culo esquerdo (diast&#243;lico - VDVE, e sist&#243;lico - VSVE), fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (FEVE) e massa ventricular esquerda.</p>
    <p>Foram avaliados os blocos volum&#233;tricos de oito pacientes, inclu&#237;dos no protocolo, para an&#225;lise da varia&#231;&#227;o intra e interobservador. Foram avaliadas as seguintes vari&#225;veis: volume diast&#243;lico e sist&#243;lico do ventr&#237;culo esquerdo, fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda, obtidos pela an&#225;lise tridimensional. Para a an&#225;lise intraobservador, foram realizadas duas an&#225;lises do mesmo bloco volum&#233;trico, por um mesmo observador, com intervalo m&#237;nimo de um m&#234;s entre as leituras.</p>
    <p>
      <bold>An&#225;lise cl&#237;nica</bold>
    </p>
    <p>Todos os pacientes foram submetidos a uma avalia&#231;&#227;o cl&#237;nica composta por anamnese, exame f&#237;sico, realiza&#231;&#227;o de eletrocardiograma de 12 deriva&#231;&#245;es, e classifica&#231;&#227;o da classe funcional segundo classifica&#231;&#227;o da NYHA (<italic>New York Heart Association</italic>), al&#233;m de avalia&#231;&#227;o da qualidade de vida pelo "Minnesota Living with Heart Failure" (MLHF).</p>
    <p>A classe funcional pela classifica&#231;&#227;o da NYHA estratifica o grau de limita&#231;&#227;o imposto pela IC nas atividades cotidianas do paciente. Essa classifica&#231;&#227;o, al&#233;m de possuir car&#225;ter funcional, &#233; tamb&#233;m uma maneira de avaliar a qualidade de vida ante a IC<sup>2</sup>. J&#225; o question&#225;rio MLHF &#233; composto por 21 perguntas que avaliam como o paciente percebe os efeitos da doen&#231;a e do seu tratamento em sua vida di&#225;ria. As quest&#245;es enfocam sintomas como dispneia, fadiga, edema, assim como o estado psicol&#243;gico e o impacto da doen&#231;a na rotina di&#225;ria e laborativa<sup>9</sup>.</p>
    <p>
      <bold>An&#225;lise ecocardiogr&#225;fica</bold>
    </p>
    <p>Os estudos ecocardiogr&#225;ficos foram realizados com o equipamento IE33 Philips Medical Systems, Andover, MA, EUA. Foram realizados os estudos ecocardiogr&#225;ficos bidimensional, an&#225;lise de fluxos card&#237;acos pelo estudo Doppler e avalia&#231;&#227;o tridimensional em tempo real. As imagens foram adquiridas nos planos paraesternal longitudinal de c&#226;maras esquerdas, transversal e apical 2, 3 e 4 c&#226;maras, de acordo com padroniza&#231;&#227;o da Sociedade Americana de Ecocardiografia<sup>10</sup>.</p>
    <p>
      <bold>An&#225;lise bidimensional</bold>
    </p>
    <p>Foram avaliados os seguintes par&#226;metros nos estudos ecocardiogr&#225;ficos: 1) di&#226;metro diast&#243;lico do ventr&#237;culo esquerdo e di&#226;metro sist&#243;lico do ventr&#237;culo esquerdo em proje&#231;&#227;o paraesternal longitudinal de c&#226;maras esquerdas; 2) volume diast&#243;lico final do ventr&#237;culo esquerdo (VDVE) (m&#233;todo de Simpson); 3) volume sist&#243;lico final do ventr&#237;culo esquerdo (VSVE) (m&#233;todo de Simpson); 4) FEVE (m&#233;todo de Simpson); 5- avalia&#231;&#227;o do fluxo mitral para a an&#225;lise da di&#225;stole ventricular com o emprego do estudo Doppler puls&#225;til.</p>
    <p>
      <bold>An&#225;lise tridimensional</bold>
    </p>
    <p>Os pacientes foram posicionados em dec&#250;bito lateral esquerdo e foi utilizado transdutor matricial X3, compat&#237;vel com o equipamento IE33, Philips Medical Systems. As imagens tridimensionais, em tempo real, foram adquiridas em apneia expirat&#243;ria (15 a 20 segundos), com a observa&#231;&#227;o do ciclo card&#237;aco a partir do registro eletrocardiogr&#225;fico. Para a avalia&#231;&#227;o dos volumes ventriculares e FEVE, os ajustes de ganho e compress&#227;o foram realizados de forma a permitir a obten&#231;&#227;o de imagens de boa qualidade t&#233;cnica e identifica&#231;&#227;o clara das bordas endoc&#225;rdicas.</p>
    <p>A obten&#231;&#227;o do bloco volum&#233;trico (<italic>Full Volume</italic>) foi feita a partir da aquisi&#231;&#227;o de quatro pequenos subvolumes, em ciclos card&#237;acos consecutivos, que, combinados, fornecem um bloco piramidal de maior volume (110&#186; x 100&#186;). Em cada aquisi&#231;&#227;o, os ajustes foram feitos de modo que a totalidade do volume ventricular esquerdo estivesse contida no bloco avaliado.</p>
    <p>Os VDVE, VSVE, e FEVE foram avaliados, posteriormente, em esta&#231;&#227;o de trabalho equipada com programa espec&#237;fico (Q-Lab, vers&#245;es 5.0. e 6.0., Philips Medical System, Andover, MA, EUA) por um algoritmo semiautom&#225;tico para a identifica&#231;&#227;o das bordas endoc&#225;rdicas. Esse programa fornece, para cada quadro adquirido, a vis&#227;o dos planos apical quatro c&#226;maras, apical duas c&#226;maras e transversal. Para a reconstru&#231;&#227;o volum&#233;trica do VE, s&#227;o identificados cinco pontos de refer&#234;ncia. A partir desses pontos de refer&#234;ncia, s&#227;o identificadas as bordas endoc&#225;rdicas para o c&#225;lculo autom&#225;tico de VDVE, VSVE e FEVE. Nos casos em que a detec&#231;&#227;o autom&#225;tica apresentou qualidade sub&#243;tima (falha na identifica&#231;&#227;o das bordas endoc&#225;rdicas), foi realizada edi&#231;&#227;o das imagens.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>A an&#225;lise estat&#237;stica foi realizada para as vari&#225;veis quantitativas cont&#237;nuas, pelo c&#225;lculo dos valores m&#237;nimos, m&#225;ximos, m&#233;dias e desvios-padr&#227;o. As vari&#225;veis qualitativas foram apresentadas em n&#250;meros absolutos, e calculadas as frequ&#234;ncias absolutas e relativas (porcentagem).</p>
    <p>A compara&#231;&#227;o entre os par&#226;metros aferidos pela ecocardiografia bidimensional e tridimensional foi efetuada com o emprego de testes de regress&#227;o linear e correla&#231;&#227;o de Pearson (r). Foi realizada a an&#225;lise da varia&#231;&#227;o intraobservador e interobservador das medidas dos volumes diast&#243;lico e sist&#243;lico do ventr&#237;culo esquerdo, fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda, por meio do c&#225;lculo do coeficiente de correla&#231;&#227;o de concord&#226;ncia.</p>
    <p>Foram utilizados o Excel (2007), para a tabula&#231;&#227;o e organiza&#231;&#227;o dos resultados, e um programa computacional para realiza&#231;&#227;o da an&#225;lise estat&#237;stica (SPSS vers&#227;o 13.0, Chicago, IL, EUA).</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Foram avaliados 63 pacientes que preencheram os crit&#233;rios de inclus&#227;o no per&#237;odo de 1&#186;.1.2007 a 1&#186;.6.2009. Este trabalho apresenta parte dos resultados de tese de doutorado (1&#186;.6.2006 a 18.6.2010), e os pacientes foram selecionados no per&#237;odo de coleta dos dados para a tese. Dos 63 pacientes avaliados no per&#237;odo, apenas 35 foram encaminhados &#224; TRC. Desses, oito pacientes evolu&#237;ram a &#243;bito antes da primeira reavalia&#231;&#227;o e foram exclu&#237;dos da an&#225;lise, uma vez que o objetivo do estudo era a avalia&#231;&#227;o do remodelamento reverso.</p>
    <p>Dos oito &#243;bitos que ocorreram antes da primeira reavalia&#231;&#227;o aos tr&#234;s meses: um paciente necessitou de transplante card&#237;aco, evoluindo a &#243;bito ap&#243;s o transplante por complica&#231;&#245;es infecciosas; um paciente apresentou parada cardiorrespirat&#243;ria (AESP - atividade el&#233;trica sem pulso) no centro cir&#250;rgico, sendo reanimado com sucesso e transferido para UTI ap&#243;s o procedimento, por&#233;m faleceu por choque cardiog&#234;nico; um paciente faleceu por choque s&#233;ptico, secund&#225;rio a infec&#231;&#227;o de loja de marca-passo; cinco pacientes faleceram por insufici&#234;ncia card&#237;aca congestiva refrat&#225;ria. A decis&#227;o de encaminhar o paciente &#224; TRC foi realizada, em conjunto, pelas equipes do Marca-passo e ICC do InCor.</p>
    <p>Assim, durante o per&#237;odo do estudo, foram avaliados 35 pacientes submetidos ao implante de MPaBiv. Ocorreram oito &#243;bitos, antes dos tr&#234;s meses de reavalia&#231;&#227;o. Dos 27 pacientes restantes, dois foram exclu&#237;dos por imagem ecocardiogr&#225;fica inadequada, e uma paciente recusou a realiza&#231;&#227;o dos exames de acompanhamento, ap&#243;s a TRC. Dessa forma, 24 pacientes realizaram reavalia&#231;&#227;o antes e seis meses ap&#243;s a TRC (fluxograma 1). Todos os pacientes concordaram em participar do estudo e assinaram o Termo de Consentimento Livre e Esclarecido.</p>
    <p>A m&#233;dia et&#225;ria dos 27 pacientes analisados foi de 58,9 &#177; 9,7 anos, sendo 10/27 (37%) dos pacientes do sexo masculino e 17/27 (63%) do sexo feminino. A etiologia da miocardiopatia foi idiop&#225;tica, na maioria dos pacientes (24/27 pacientes; 89%), e chag&#225;sica em 3/27 pacientes (11%). A maioria dos pacientes (21/27 pacientes; 77,8%) era portadora de hipertens&#227;o arterial sist&#234;mica, enquanto 6/27 pacientes (22,2%) apresentavam antecedente de diabete melito (<xref ref-type="table" rid="tab1">tab. 1</xref>).</p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gt01.jpg"/></table-wrap>
    <p>Em rela&#231;&#227;o ao tratamento medicamentoso, 26/27 pacientes (96,3%) estavam em uso de inibidores da enzima de convers&#227;o da angiotensina (iECAs) ou bloqueadores do receptor da angiotensina II (BRAs); 26/27 pacientes (96,3%), em uso de betabloqueadores e diur&#233;ticos; 25/27 pacientes (92,3%), em uso de espironolactona; e 16/27 pacientes (59,3%), em uso de digoxina. O tratamento foi mantido, sem altera&#231;&#245;es, durante todo o per&#237;odo de seguimento (<xref ref-type="table" rid="tab1">tab. 1</xref>).</p>
    <p>Com rela&#231;&#227;o &#224; evolu&#231;&#227;o cl&#237;nica, ap&#243;s tr&#234;s meses da TRC, houve melhora da CF (NYHA), p &lt; 0,001, de pelo menos um grau em 18/24 (75%) dos pacientes e manuten&#231;&#227;o da CF em 6/24 (25%) dos pacientes. Aos seis meses ap&#243;s a TRC, 19/24 (79%) mantiveram a melhora na CF (NYHA) e 5/24 (21%) n&#227;o apresentaram altera&#231;&#245;es da CF, p &lt; 0,001 (<xref ref-type="fig" rid="aop06511fig01">fig. 1A</xref>). Tamb&#233;m foi evidenciada melhora da qualidade de vida, avaliada pelo escore de Minnesota (MLHFQ), aos tr&#234;s meses ap&#243;s TRC, em 21/24 (88%) dos pacientes, piora em 1/24 (4%), e 2/24 (8%) dos pacientes n&#227;o apresentaram altera&#231;&#245;es (p &lt; 0,001). Aos seis meses ap&#243;s a TRC, 20/24 (83%) dos pacientes apresentaram melhora do MLHFQ, 3/24 (13%) apresentaram piora e 1/24 (4%) paciente n&#227;o apresentou altera&#231;&#245;es, p &lt; 0,001 (<xref ref-type="fig" rid="aop06511fig01">fig. 1B</xref>).</p>
    <p><fig id="aop06511fig01"/>&#13;
&#160;&#13;
&#160;&#13;
</p>
    <p>
      <fig id="aop06511fig01a">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf01.jpg"/></fig>
    </p>
    <p>&#13;
  <fig id="aop06511fig01xb"/><fig id="aop06511fig01b"><graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf02.jpg"/></fig></p>
    <p>A an&#225;lise dos volumes ventriculares pelo modo bidimensional, por meio do m&#233;todo de Simpson (VDVE: 283 &#177; 117 ml; VSVE: 219 &#177; 93 ml no momento basal), revelou redu&#231;&#227;o dos volumes ventriculares diast&#243;lico e sist&#243;lico do ventr&#237;culo esquerdo (VDVE: 262 &#177; 124 ml, p = 0,018; VSVE: 196 &#177; 105 ml, p = 0,007) ap&#243;s tr&#234;s meses da TRC. Essa redu&#231;&#227;o manteve-se na avalia&#231;&#227;o ap&#243;s seis meses da TRC (VDVE: 256 &#177; 137 ml, p = 0,038; VSVE:185 &#177; 114 ml, p = 0,027) (<xref ref-type="table" rid="aop06511tab02">tab. 2</xref>; <xref ref-type="fig" rid="aop06511fig02">fig. 2</xref> e <xref ref-type="fig" rid="aop06511fig03">3</xref>).</p>
    <p content-type="asset">
      <table-wrap id="aop06511tab02">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gt02.jpg"/></table-wrap>
    </p>
    <p content-type="asset">
      <fig id="aop06511fig02">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf03.jpg"/></fig>
    </p>
    <p content-type="asset">
      <fig id="aop06511fig03">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf04.jpg"/></fig>
    </p>
    <p>A fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (0,23 &#177; 0,05), avaliada pelo m&#233;todo de Simpson, tamb&#233;m apresentou melhora aos tr&#234;s meses (0,28 &#177; 0,07, p = 0,028) ap&#243;s TRC, e a qual se manteve aos seis meses (0,28 &#177; 0,10, p = 0,006), ap&#243;s TRC (<xref ref-type="table" rid="aop06511tab02">tab. 2</xref>) (<xref ref-type="fig" rid="aop06511fig04">fig. 4</xref>).</p>
    <p content-type="asset">
      <fig id="aop06511fig04">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf05.jpg"/></fig>
    </p>
    <p>A an&#225;lise pelo Eco 3D evidenciou m&#233;dias e desvio-padr&#227;o dos volumes ventriculares diast&#243;lico e sist&#243;lico de 252 &#177; 105 ml e 194 &#177; 86 ml, respectivamente, no momento basal. Ap&#243;s a TRC, houve redu&#231;&#227;o n&#227;o significativa dos volumes ventriculares, avaliados ao Eco 3D. Aos tr&#234;s meses ap&#243;s TRC, houve redu&#231;&#227;o de 25 ml (10%) da m&#233;dia dos valores de VDVE e de 26 ml (13%) da m&#233;dia dos valores de VSVE, em rela&#231;&#227;o ao momento basal (VDVE: 227 &#177; 113 ml, p = 0,187; VSVE: 168 &#177; 95 ml, p = 0,065). Aos seis meses ap&#243;s TRC, a redu&#231;&#227;o do VDVE foi de 13 ml (5%) e de 6 ml (6%) do VSVE, em rela&#231;&#227;o ao momento basal (VDVE: 239 + 129 ml, p = 0,163; VSVE: 183 + 115 ml, p = 0,347) (<xref ref-type="table" rid="aop06511tab02">tab. 2</xref>; <xref ref-type="fig" rid="aop06511fig02">fig. 2</xref> e <xref ref-type="fig" rid="aop06511fig03">3</xref>). Com rela&#231;&#227;o &#224; FEVE, houve melhora (21,7%), em rela&#231;&#227;o ao momento basal (FEVE: 0,23 &#177; 0,05), evidenciada aos tr&#234;s meses, ap&#243;s TRC (FEVE: 0,28 &#177; 0,07, p = 0,008) e que se manteve aos seis meses (FEVE: 0,28 &#177; 0,10; p = 0,033) (<xref ref-type="table" rid="aop06511tab02">tab. 2</xref>; <xref ref-type="fig" rid="aop06511fig04">fig. 4</xref>).</p>
    <p>N&#227;o houve varia&#231;&#227;o da massa ventricular esquerda aos tr&#234;s meses (p = 0,511 pelo Eco 3D) e seis meses (p = 0,706 ao Eco 2D, p = 0,479 ao Eco 3D), ap&#243;s a TRC (<xref ref-type="table" rid="aop06511tab02">tab. 2</xref>).</p>
    <p>No momento basal, a correla&#231;&#227;o entre os m&#233;todos foi de 0,96 para avalia&#231;&#227;o do VDVE, 0,95 para avalia&#231;&#227;o do VSVE, 0,87 para FEVE e 0,72 para massa do VE. Ap&#243;s tr&#234;s meses da TRC, a correla&#231;&#227;o entre o Eco 2D e 3D para an&#225;lise do VDVE foi de 0,96, 0,95 para VSVE, 0,95 para FEVE e 0,77 para massa do VE. Ap&#243;s seis meses da TRC, a correla&#231;&#227;o entre o Eco 2D e 3D para an&#225;lise do VDVE foi de 0,98, 0,91 para VSVE, 0,96 para FEVE e 0,85 para massa do VE (<xref ref-type="fig" rid="aop06511fig05">fig. 5</xref> e <xref ref-type="fig" rid="aop06511fig06">6</xref>).</p>
    <p content-type="asset">
      <fig id="aop06511fig05">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf06.jpg"/></fig>
    </p>
    <p content-type="asset">
      <fig id="aop06511fig06">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf07.jpg"/></fig>
    </p>
    <p>Com rela&#231;&#227;o &#224; avalia&#231;&#227;o da varia&#231;&#227;o intra e interobservador pelo Eco 3D, o coeficiente de correla&#231;&#227;o de concord&#226;ncia (CCC) da an&#225;lise do VDVE intraobservador foi de 0,95 (95% Intervalo de confian&#231;a: 0,80 a 0,99) e o do interobservador foi de 0,95 (95% Intervalo de confian&#231;a: 0,77 a 0,99). O CCC da an&#225;lise do VSVE intraobservador foi de 0,97 (95% Intervalo de confian&#231;a: 0,86 a 0,99) e o do interobservador foi de 0,95 (95% Intervalo de confian&#231;a: 0,81 a 0,99). O CCC da an&#225;lise da FEVE intraobservador foi de 0,97 (95% Intervalo de confian&#231;a: 0,86 a 0,99) e o do interobservador foi de 0,92 (95% Intervalo de confian&#231;a: 0,71 a 0,98).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Em pacientes com IC avan&#231;ada, a dilata&#231;&#227;o ventricular esquerda importante &#233; considerada fator independente de pior progn&#243;stico<sup>11</sup>. Pacientes com miocardiopatia dilatada idiop&#225;tica e dilata&#231;&#227;o ventricular importante apresentam diminui&#231;&#227;o da reserva de fluxo coron&#225;rio, detectada em estudos de perfus&#227;o mioc&#225;rdica com t&#233;cnicas de medicina nuclear e pela ecocardiografia sob estresse farmacol&#243;gico com dipiridamol<sup>12-14</sup>. Esses achados est&#227;o associados ao maior estresse sist&#243;lico na parede ventricular esquerda e a &#225;reas de consumo anormal de oxig&#234;nio sugerindo a presen&#231;a de isquemia e pior progn&#243;stico nestes pacientes.</p>
    <p>Portanto, pacientes com IC grave e dilata&#231;&#227;o ventricular importante, evidenciada pelo aumento do DDVE e dos volumes ventriculares, podem apresentar pior resposta &#224; TRC em raz&#227;o de menor reserva de fluxo coron&#225;rio e de presen&#231;a de &#225;reas com padr&#227;o anormal do consumo de oxig&#234;nio. A avalia&#231;&#227;o do grau de dilata&#231;&#227;o ventricular analisada pela ecocardiografia 2D e 3D no momento basal fornece informa&#231;&#245;es importantes a respeito da evolu&#231;&#227;o dos pacientes ap&#243;s a TRC. Assim, sabe-se da import&#226;ncia da avalia&#231;&#227;o dos VSVE e VDVE antes da TRC.</p>
    <p>Em estudo de Ant&#243;nio e cols.<sup>15</sup>, pacientes em fases mais precoces de miocardiopatia e menores altera&#231;&#245;es na geometria ventricular apresentaram maior probabilidade de resposta com a TRC. Adicionalmente, a avalia&#231;&#227;o das altera&#231;&#245;es volum&#233;tricas ap&#243;s a TRC fornece informa&#231;&#245;es preditivas importantes a respeito dos desfechos cl&#237;nicos na evolu&#231;&#227;o natural da doen&#231;a, conforme demonstrado inicialmente por Yu e cols.<sup>16</sup> e confirmado em estudo recente de Ypenburg e cols.<sup>17</sup>. Dados a respeito da utiliza&#231;&#227;o de terapias farmacol&#243;gicas enfatizam a import&#226;ncia do remodelamento reverso ventricular esquerdo no progn&#243;stico em longo prazo, tornando, dessa forma, essa vari&#225;vel muito &#250;til como marcador de melhora cl&#237;nica. No estudo de Ypenburg e cols.<sup>17</sup>, a extens&#227;o do remodelamento reverso apresentou ainda correla&#231;&#227;o com o progn&#243;stico em longo prazo: quanto maior a taxa de remodelamento reverso, melhor a evolu&#231;&#227;o cl&#237;nica e vice-versa.</p>
    <p>O valor da ecocardiografia tridimensional na avalia&#231;&#227;o dos volumes ventriculares, fra&#231;&#227;o de eje&#231;&#227;o e massa ventricular esquerda j&#225; foi comprovado em diversos estudos, com excelente correla&#231;&#227;o de resultados quando comparado &#224; resson&#226;ncia magn&#233;tica card&#237;aca<sup>5,6</sup>. A aquisi&#231;&#227;o dos blocos volum&#233;tricos, por meio do Eco 3D, para avalia&#231;&#227;o desses par&#226;metros, pode ser realizada rapidamente, com a utiliza&#231;&#227;o de um transdutor matricial, e a quantifica&#231;&#227;o dos dados, por um operador treinado e experiente, dura em m&#233;dia de seis a oito minutos<sup>18,19</sup>.</p>
    <p>Desse modo, o Eco 3D constitui-se em uma ferramenta muito &#250;til na avalia&#231;&#227;o ecocardiogr&#225;fica, aumentando a precis&#227;o dos c&#225;lculos dos volumes, FEVE e massa ventricular esquerda, sem aumentar de maneira significativa a dura&#231;&#227;o do exame. Por&#233;m, atualmente, o Eco 3D ainda n&#227;o &#233; amplamente dispon&#237;vel, requer equipamentos e programas computacionais espec&#237;ficos para a quantifica&#231;&#227;o dos dados, al&#233;m de exigir treinamento adequado para a aquisi&#231;&#227;o de blocos volum&#233;tricos de boa qualidade t&#233;cnica.</p>
    <p>A ecocardiografia bidimensional, por sua vez, &#233; amplamente dispon&#237;vel e tem sido o m&#233;todo mais utilizado na avalia&#231;&#227;o de pacientes candidatos &#224; TRC e na avalia&#231;&#227;o da resposta ap&#243;s essa terap&#234;utica.</p>
    <p>Neste estudo, foi comparada a avalia&#231;&#227;o dos dados a respeito da morfologia e fun&#231;&#227;o ventricular esquerda pelo Eco 2D e 3D, no momento pr&#233;-TRC, o que auxilia na sele&#231;&#227;o dos candidatos a TRC, e tr&#234;s e seis meses ap&#243;s a TRC, a fim de se avaliar a resposta ao tratamento.</p>
    <p>A avalia&#231;&#227;o dos volumes ventriculares ap&#243;s a TRC &#233; importante no reconhecimento do remodelamento reverso ventricular esquerdo, definido como redu&#231;&#227;o dos volumes diast&#243;lico e sist&#243;lico do ventr&#237;culo esquerdo e melhora da FEVE. A identifica&#231;&#227;o do remodelamento reverso pela ecocardiografia tem import&#226;ncia progn&#243;stica, uma vez que a resposta volum&#233;trica tem apresentado melhor valor preditivo de sobrevida livre de eventos e mortalidade, quando comparada com a resposta cl&#237;nica avaliada pela melhora da classe funcional (NYHA) e da qualidade vida<sup>16,20</sup>. Uma vez comprovada a superioridade do Eco 3D, em rela&#231;&#227;o ao Eco 2D, na avalia&#231;&#227;o dos volumes ventriculares, massa e FEVE, &#233; fundamental avaliar a concord&#226;ncia entre essas duas t&#233;cnicas, pois o Eco 2D &#233; o m&#233;todo mais utilizado em pacientes submetidos a TRC.</p>
    <p>Os volumes ventriculares (VDVE e VSVE) avaliados tanto pelo m&#233;todo de Simpson como pelo Eco 3D fornecem informa&#231;&#245;es adicionais &#224; sele&#231;&#227;o dos pacientes e &#224; taxa de resposta &#224; TRC. A melhora e o grau de melhora da FEVE avaliada ap&#243;s a TRC apresentam boa correla&#231;&#227;o com a melhora na evolu&#231;&#227;o clinica dos pacientes submetidos &#224; TRC. Segundo Di Biase e cols.<sup>21</sup>, o aumento de seis pontos ou mais na FEVE aos tr&#234;s meses ap&#243;s a TRC apresenta taxa ao redor de 66% livre de eventos em cinco anos de seguimento.</p>
    <p>Neste estudo, houve melhora significativa da FEVE avaliada por ambos os m&#233;todos (Simpson e Eco 3D) tr&#234;s meses ap&#243;s a TRC e que se manteve aos seis meses da TRC na amostra total do estudo. Houve ainda excelente correla&#231;&#227;o entre os m&#233;todos para a aferi&#231;&#227;o volum&#233;trica ventricular esquerda durante todas as fases do estudo, o que demonstra a utilidade da ecocardiografia bidimensional no acompanhamento e avalia&#231;&#227;o do remodelamento reverso dos pacientes submetidos a TRC, enquanto o Eco 3D n&#227;o &#233; parte da avalia&#231;&#227;o ecocardiogr&#225;fica na pr&#225;tica cl&#237;nica di&#225;ria.</p>
    <p>A avalia&#231;&#227;o da massa do VE pelo Eco 3D &#233; superior ao Eco 2D, quando comparada &#224; RMC. &#201; importante notar que apesar da boa correla&#231;&#227;o entre os Ecos 2D e 3D para avalia&#231;&#227;o da massa, o Eco 3D &#233; mais acurado, justificando seu uso quando dispon&#237;vel. Por&#233;m, apesar da superioridade do Eco 3D para avalia&#231;&#227;o dos volumes, massa e fun&#231;&#227;o ventricular esquerda em rela&#231;&#227;o ao Eco 2D (quando comparados &#224; RMC, que &#233; atualmente o m&#233;todo padr&#227;o de refer&#234;ncia para essas an&#225;lises), o Eco 2D &#233; o m&#233;todo mais utilizado na pratica clinica por sua disponibilidade e custo. Dessa forma, os resultados deste estudo, ao demonstrar a excelente correla&#231;&#227;o entre os m&#233;todos (Ecos 2D e 3D), torna o Eco 2D um m&#233;todo confi&#225;vel para a avalia&#231;&#227;o do remodelamento reverso ap&#243;s a TRC.</p>
    <p>
      <xref ref-type="fig" rid="aop06511fig07">Figura 7</xref>
    </p>
    <p content-type="asset">
      <fig id="aop06511fig07">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf08.jpg"/></fig>
    </p>
    <p>
      <bold>Limita&#231;&#245;es do estudo</bold>
    </p>
    <p>Houve discreto aumento do volume ventricular entre os tr&#234;s e seis meses ap&#243;s a TRC, detectado ao Eco 3D. Acreditamos que esse achado ainda seja decorrente das limita&#231;&#245;es inerentes &#224; tecnologia atual dos equipamentos de Eco 3D. Os pacientes inclu&#237;dos neste estudo apresentavam valores muito altos de DDVE e dilata&#231;&#227;o importante dos volumes ventriculares, o que dificultou a inclus&#227;o de todo o ventr&#237;culo esquerdo na aquisi&#231;&#227;o do bloco tridimensional. Apesar de terem sido exclu&#237;dos os blocos com impossibilidade de avalia&#231;&#227;o de dois ou mais segmentos mioc&#225;rdicos, a dificuldade na avalia&#231;&#227;o da parede lateral ao plano coronal e das paredes inferior e anterior, no plano sagital, podem ter limitado o c&#225;lculo dos volumes ventriculares esquerdos ao Eco 3D. Al&#233;m disso, limita&#231;&#245;es no grau de abertura do feixe ultrass&#244;nico e o baixo <italic>frame rate</italic> (20 a 30 volumes/segundo) do Eco 3D, tamb&#233;m, podem ter resultado na diferen&#231;a n&#227;o significativa entre os volumes ventriculares esquerdos dos GI e GII, antes da TRC.</p>
    <p>O Eco 3D, apesar de dispon&#237;vel h&#225; cerca de quatro d&#233;cadas, ainda n&#227;o chegou a seu formato definitivo e apresenta limita&#231;&#245;es f&#237;sicas e em seu formato de apresenta&#231;&#227;o em diferentes programas de aquisi&#231;&#227;o, leitura e de interpreta&#231;&#227;o. O desenvolvimento do Eco 3D ir&#225; sem d&#250;vida permitir trabalhar em futuro pr&#243;ximo com pacientes que apresentem grandes dilata&#231;&#245;es ventriculares e que apresentem acentuada varia&#231;&#227;o de ritmo card&#237;aco (fibrila&#231;&#227;o atrial) e ritmo respirat&#243;rio.</p>
    <p>Outra limita&#231;&#227;o refere-se &#224; n&#227;o utiliza&#231;&#227;o da resson&#226;ncia magn&#233;tica card&#237;aca na avalia&#231;&#227;o dos volumes ventriculares e FEVE para compara&#231;&#227;o com os Ecos 2D e 3D, uma vez que esse &#233; o m&#233;todo considerado padr&#227;o de refer&#234;ncia para essa finalidade.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Neste estudo, foi observada redu&#231;&#227;o dos volumes diast&#243;lico e sist&#243;lico do ventr&#237;culo esquerdo, al&#233;m de melhora da FEVE ap&#243;s a TRC. Houve excelente correla&#231;&#227;o entre os Ecos 2D e 3D para avalia&#231;&#227;o dos volumes ventriculares e fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda, e boa correla&#231;&#227;o entre os m&#233;todos para avalia&#231;&#227;o da massa ventricular esquerda antes e ap&#243;s a TRC.</p>
    <p>
      <bold>Potencial conflito de interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado pela SOCESP (Bolsa de estudos de julho 2009 a julho 2010).</p>
    <p>
      <bold>Vincula&#231;&#227;o acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte da tese de Doutorado de Viviane Tiemi Hotta pela Faculdade de Medicina da USP.</p>
    <p>
      <fn id="ab1" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Viviane Tiemi Hotta </p>
        <p> Rua Periquito, 160/ 22 - Vila Uberabinha </p>
        <p> 04514-050 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="alesq@terra.com.br">alesq@terra.com.br</email>, </p>
        <p>
          <email xlink:href="editoracao-pc@cardiologia.org.br">editoracao-pc@cardiologia.org.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 22/09/10; revisado recebido em 08/11/10; aceito em 28/01/11.</p>
    <p>Full texts in English - <ext-link ext-link-type="uri" xlink:href="http://www.arquivosonline.com.br"><italic>http://www.arquivosonline.com.br</italic></ext-link></p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society. Circulation. 2009;119(14):1977-2016.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1977</fpage>
          <lpage>2016</lpage>
          <issue>14</issue>
          <volume>119</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jessup</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Casey</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Ganiats</surname>
              <given-names>TG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Bocchi EA, Marcondes-Braga FG, Ayub-Ferreira SM, Rohde LE, Oliveira WA, Almeida DR, et al; Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica. Arq Bras Cardiol. 2009;93(1 supl.1):1-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <issue>1</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Marcondes-Braga</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Ayub-Ferreira</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289(6):730-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials</article-title>
          <source>JAMA</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>730</fpage>
          <lpage>40</lpage>
          <issue>6</issue>
          <volume>289</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bradley</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Bradley</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Baughman</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Calkins</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-49.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators: The effect of cardiac resynchronization on morbidity and mortality in heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1539</fpage>
          <lpage>49</lpage>
          <issue>15</issue>
          <volume>352</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cleland</surname>
              <given-names>JGF</given-names>
            </name>
            <name>
              <surname>Daubert</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Erdmann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Freemantle</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gras</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kappenberger</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Mannaerts HF, Van Der Heide JA, Kamp O, Papavassiliu T, Marcus JT, Beek A, et al. Quantification of left ventricular volumes and ejection fraction using freehand transthoracic three-dimensional echocardiography: comparison with magnetic resonance imaging. J Am Soc Echocardiogr. 2003;16(2):101-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Quantification of left ventricular volumes and ejection fraction using freehand transthoracic three-dimensional echocardiography: comparison with magnetic resonance imaging</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>101</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mannaerts</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Van Der Heide</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kamp</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Papavassiliu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Marcus</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Beek</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Hotta VT, Cruz CBBV, Rassi DC, Vieira MLC, Mathias Jr W, Avila LFR, et al. Subvalvular mitral pseudoaneurysm evaluated by three-dimensional echo. Echocardiography. 2010;27(4):473-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Subvalvular mitral pseudoaneurysm evaluated by three-dimensional echo</article-title>
          <source>Echocardiography</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>473</fpage>
          <lpage>5</lpage>
          <issue>4</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hotta</surname>
              <given-names>VT</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>CBBV</given-names>
            </name>
            <name>
              <surname>Rassi</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>MLC</given-names>
            </name>
            <name>
              <surname>Mathias Jr</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Avila</surname>
              <given-names>LFR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Ritter P, Padeletti L, Gillio-Meina L, Gaggini G. Determination of the optimal atrioventricular delay in DDD pacing: comparison between echo and peak endocardial acceleration measurements. Europace. 1999;1(2):126-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Determination of the optimal atrioventricular delay in DDD pacing: comparison between echo and peak endocardial acceleration measurements</article-title>
          <source>Europace</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>126</fpage>
          <lpage>30</lpage>
          <issue>2</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ritter</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Padeletti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gillio-Meina</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gaggini</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Ritter P, Dib JC, Lelievre T. Quick determination of the optimal AV delay at rest in patients paced in DDD mode for complete AV block. Eur J Cardiac Pacing Electrophysiol.1994;4:A163.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Quick determination of the optimal AV delay at rest in patients paced in DDD mode for complete AV block</article-title>
          <source>Eur J Cardiac Pacing Electrophysiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>A163</fpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ritter</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dib</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lelievre</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Carvalho VO, Guimar&#227;es GV, Carrara D, Bacal F, Bocchi EA. Valida&#231;&#227;o da vers&#227;o em portugu&#234;s do Minnesota Living with Heart Failure Questionnaire. Arq Bras Cardiol. 2009;93(1):39-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Valida&#231;&#227;o da vers&#227;o em portugu&#234;s do Minnesota Living with Heart Failure Questionnaire</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>39</fpage>
          <lpage>44</lpage>
          <issue>1</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>VO</given-names>
            </name>
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Carrara</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>539</fpage>
          <lpage>42</lpage>
          <issue>4</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cerqueira</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Weissman</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Dilsizian</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Kaul</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Laskey</surname>
              <given-names>WK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Lee TH, Hamilton MA, Stevenson LW, Moriguchi JD, Fonarow GC, Child JS, et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993;72(9):672-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impact of left ventricular cavity size on survival in advanced heart failure</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>672</fpage>
          <lpage>6</lpage>
          <issue>9</issue>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Moriguchi</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Fonarow</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Child</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002;105(2):186-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>186</fpage>
          <lpage>93</lpage>
          <issue>2</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Neglia</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Michelassi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Trivieri</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Sambuceti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giorgetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pratali</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Morales MA, Neglia D, L'Abbate A. Reduction of myocardial blood flow reserve in idiopathic dilated cardiomyopathy without overt heart failure and its relation with functional indices: an echo-Doppler and positron emission tomography study. J Cardiovasc Med (Hagerstown). 2008;9(8):778-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reduction of myocardial blood flow reserve in idiopathic dilated cardiomyopathy without overt heart failure and its relation with functional indices: an echo-Doppler and positron emission tomography study</article-title>
          <source>J Cardiovasc Med (Hagerstown)</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>778</fpage>
          <lpage>82</lpage>
          <issue>8</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morales</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Neglia</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>L'Abbate</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;35(1):19-28.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>19</fpage>
          <lpage>28</lpage>
          <issue>1</issue>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>van den Heuvel</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>van Veldhuisen</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>van der Wall</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Blanksma</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Siebelink</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Vaalburg</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Ant&#243;nio N, Teixeira R, Coelho L, Louren&#231;o C, Monteiro P, Ventura M, et al. Identification of 'super-responders' to cardiac resynchronization therapy: the importance of symptom duration and left ventricular geometry. Europace. 2009;11(3):343-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Identification of 'super-responders' to cardiac resynchronization therapy: the importance of symptom duration and left ventricular geometry</article-title>
          <source>Europace</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>343</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ant&#243;nio</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Teixeira</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Louren&#231;o</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Monteiro</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ventura</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112(11):1580-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1580</fpage>
          <lpage>6</lpage>
          <issue>11</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Bleeker</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Schalij</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>van der Wall</surname>
              <given-names>EE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Ypenburg C, van Bommel RJ, Borleffs CJ, Bleeker GB, Boersma E, Schalij MJ, et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol. 2009;53(6):483-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>483</fpage>
          <lpage>90</lpage>
          <issue>6</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ypenburg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>van Bommel</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Borleffs</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Bleeker</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Boersma</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schalij</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Kapetanakis S, Kearney MT, Siva A, Gall N, Cooklin M, Monaghan MJ. Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation. 2005;112(7):992-1000.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>992</fpage>
          <lpage>1000</lpage>
          <issue>7</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kapetanakis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kearney</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Siva</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gall</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cooklin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Monaghan</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Marsan NA, Bleeker GB, Ypenburg C, Ghio S, van de Veire NR, Holman ER, et al. Real-time three-dimensional echocardiography permits quantification of left ventricular mechanical dyssynchrony and predicts acute response to cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2008;19(4):392-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Real-time three-dimensional echocardiography permits quantification of left ventricular mechanical dyssynchrony and predicts acute response to cardiac resynchronization therapy</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>392</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Marsan</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Bleeker</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Ypenburg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ghio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>van de Veire</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Holman</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Bleeker GB, Bax JJ, Fung JW, van der Wall EE, Zhang Q, Schalij MJ, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97(2):260-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>260</fpage>
          <lpage>3</lpage>
          <issue>2</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bleeker</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>van der Wall</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Schalij</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Di Biase L, Auricchio A, Sorgente A, Civello K, Klersy C, Faletra F, et al. The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy. Eur Heart J. 2008;29(20):2497-505.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>2497</fpage>
          <lpage>505</lpage>
          <issue>20</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Di Biase</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Auricchio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sorgente</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Civello</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Klersy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Faletra</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Comparaci&#243;n entre la ecocardiograf&#237;a 2D y 3D en la evaluaci&#243;n del remodelado reverso despu&#233;s de la TRC</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La ecocardiograf&#237;a consiste en m&#233;todo muy &#250;til para selecci&#243;n y evaluaci&#243;n de respuesta a la terapia de resincronizaci&#243;n card&#237;aca (TRC). El ecocardiograma tridimensional ya tiene su papel establecido en la evaluaci&#243;n de los vol&#250;menes ventriculares y fracci&#243;n de eyecci&#243;n ventricular izquierda (FEVI) con excelente correlaci&#243;n de resultados cuando es comparado a la resonancia nuclear magn&#233;tica (RNM). OBJETIVO: Comparar la evaluaci&#243;n de los vol&#250;menes ventriculares (VDVI, VSVI), FEVI y masa del VI antes y despu&#233;s de la TRC por la ecocardiograf&#237;a bi (Eco 2D) y tridimensional (Eco 3D). M&#201;TODOS: Fueron evaluados 24 pacientes con insuficiencia card&#237;aca (IC), clase funcional (CF) III o IV (NYHA), ritmo sinusal QRS &gt; 120 ms, en vigencia de terap&#233;utica optimizada para IC sometidos a TRC. Fueron realizados electrocardiograma (ECG), evaluaci&#243;n cl&#237;nica, Eco 2D y 3D antes, tres y seis meses despu&#233;s de la TRC. La comparaci&#243;n entre las t&#233;cnicas fue realizada utilizando la correlaci&#243;n de Pearson (r). RESULTADOS: En el momento basal, la correlaci&#243;n entre los m&#233;todos fue de 0,96 para evaluaci&#243;n del VDVI, 0,95 para evaluaci&#243;n del VSVI, 0,87 para FEVI, y 0,72 para masa del VI. Despu&#233;s de tres meses de la TRC, la correlaci&#243;n entre los m&#233;todos para an&#225;lisis del VDVI fue de 0,96, 0,95 para VSVI, 0,95 para FEVI, y 0,77 para masa del VI. Despu&#233;s de seis meses de la TRC, la correlaci&#243;n entre el Eco 2D y 3D para an&#225;lisis del VDVI fue de 0,98, 0,91 para VSVI, 0,96 para FEVI, y 0,85 para masa del VI. CONCLUSI&#211;N: En este estudio fue observada reducci&#243;n de los VDVI,VSVI, adem&#225;s de mejora de la FEVI despu&#233;s de la TRC. Hubo excelente correlaci&#243;n entre el Eco 2D y el 3D para evaluaci&#243;n de los vol&#250;menes ventriculares y FEVI, y buena correlaci&#243;n entre los m&#233;todos para evaluaci&#243;n de la masa ventricular izquierda antes y despu&#233;s de la TRC.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Ecocardiograf&#237;a</kwd>
        <kwd>ecocardiograf&#237;a tridimensional</kwd>
        <kwd>volumen sist&#243;lico</kwd>
        <kwd>disfunci&#243;n ventricular izquierda</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ESPECIAL</bold>
      </p>
      <p>
        <fn id="nota_1-body2">
          <label>
            <bold>Comparaci&#243;n entre la ecocardiograf&#237;a 2D y 3D en la evaluaci&#243;n del remodelado reverso despu&#233;s de la TRC</bold>
          </label>
          <p>
            <bold>Viviane Tiemi Hotta<sup>I,II</sup>; Martino Martinelli Filho<sup>I</sup>; Charles Mady<sup>II</sup>; Wilson Mathias Jr<sup>I</sup>; Marcelo Luiz Campos Vieira<sup>I,III</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Instituto do Cora&#231;&#227;o (InCor) da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brasil</p>
      <p><sup>II</sup>Fleury Medicina e Sa&#250;de, S&#227;o Paulo, SP - Brasil</p>
      <p><sup>III</sup>Hospital Israelita Albert Einstein, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La ecocardiograf&#237;a consiste en m&#233;todo muy &#250;til para selecci&#243;n y evaluaci&#243;n de respuesta a la terapia de resincronizaci&#243;n card&#237;aca (TRC). El ecocardiograma tridimensional ya tiene su papel establecido en la evaluaci&#243;n de los vol&#250;menes ventriculares y fracci&#243;n de eyecci&#243;n ventricular izquierda (FEVI) con excelente correlaci&#243;n de resultados cuando es comparado a la resonancia nuclear magn&#233;tica (RNM).</p>
      <p><bold>OBJETIVO:</bold> Comparar la evaluaci&#243;n de los vol&#250;menes ventriculares (VDVI, VSVI), FEVI y masa del VI antes y despu&#233;s de la TRC por la ecocardiograf&#237;a bi (Eco 2D) y tridimensional (Eco 3D).</p>
      <p><bold>M&#201;TODOS:</bold> Fueron evaluados 24 pacientes con insuficiencia card&#237;aca (IC), clase funcional (CF) III o IV (NYHA), ritmo sinusal QRS <underline>&gt;</underline> 120 ms, en vigencia de terap&#233;utica optimizada para IC sometidos a TRC. Fueron realizados electrocardiograma (ECG), evaluaci&#243;n cl&#237;nica, Eco 2D y 3D antes, tres y seis meses despu&#233;s de la TRC. La comparaci&#243;n entre las t&#233;cnicas fue realizada utilizando la correlaci&#243;n de Pearson (r).</p>
      <p><bold>RESULTADOS:</bold> En el momento basal, la correlaci&#243;n entre los m&#233;todos fue de 0,96 para evaluaci&#243;n del VDVI, 0,95 para evaluaci&#243;n del VSVI, 0,87 para FEVI, y 0,72 para masa del VI. Despu&#233;s de tres meses de la TRC, la correlaci&#243;n entre los m&#233;todos para an&#225;lisis del VDVI fue de 0,96, 0,95 para VSVI, 0,95 para FEVI, y 0,77 para masa del VI. Despu&#233;s de seis meses de la TRC, la correlaci&#243;n entre el Eco 2D y 3D para an&#225;lisis del VDVI fue de 0,98, 0,91 para VSVI, 0,96 para FEVI, y 0,85 para masa del VI.</p>
      <p><bold>CONCLUSI&#211;N:</bold> En este estudio fue observada reducci&#243;n de los VDVI,VSVI, adem&#225;s de mejora de la FEVI despu&#233;s de la TRC. Hubo excelente correlaci&#243;n entre el Eco 2D y el 3D para evaluaci&#243;n de los vol&#250;menes ventriculares y FEVI, y buena correlaci&#243;n entre los m&#233;todos para evaluaci&#243;n de la masa ventricular izquierda antes y despu&#233;s de la TRC.</p>
      <p><bold>Palabras clave:</bold> Ecocardiograf&#237;a, ecocardiograf&#237;a tridimensional, volumen sist&#243;lico, disfunci&#243;n ventricular izquierda.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La ecocardiograf&#237;a consiste en m&#233;todo muy &#250;til para selecci&#243;n y evaluaci&#243;n de respuesta a la terapia de resincronizaci&#243;n card&#237;aca (TRC) para pacientes con insuficiencia card&#237;aca (IC) grave y trastorno de la conducci&#243;n ventricular<sup>1-4</sup>. El ecocardiograma tridimensional (Eco 3D) ya tiene su papel establecido en la evaluaci&#243;n de los vol&#250;menes ventriculares y fracci&#243;n de eyecci&#243;n ventricular izquierda (FEVI) con excelente correlaci&#243;n de resultados cuando es comparado a la resonancia magn&#233;tica card&#237;aca<sup>5,6</sup>. En relaci&#243;n al ecocardiograma bidimensional (Eco 2D), el Eco 3D presenta mayor proximidad a la anatom&#237;a real en raz&#243;n de la ausencia de inferencias geom&#233;tricas.</p>
      <p>Una vez que el Eco 2D tiene mayor disponibilidad y ha sido el m&#233;todo m&#225;s utilizado para el control de esos pacientes, demostramos en este estudio su correlaci&#243;n con el Eco 3D en la evaluaci&#243;n de los vol&#250;menes ventriculares (volumen diast&#243;lico final del ventr&#237;culo izquierdo y volumen sist&#243;lico final del ventr&#237;culo izquierdo), fracci&#243;n de eyecci&#243;n y masa ventricular izquierda antes y despu&#233;s de la TRC.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Fue realizado estudio prospectivo y observacional, en el per&#237;odo de 1/1/2007 a 1/6/2009. El proyecto fue aprobado por la Comisi&#243;n Cient&#237;fica y de &#201;tica del InCor -HCFMUSP, por la Comisi&#243;n de &#201;tica para el An&#225;lisis de Proyectos de Investigaci&#243;n (CAPPesq), de la Direcci&#243;n Cl&#237;nica del Hospital das Cl&#237;nicas de la Universidad de S&#227;o Paulo. Este estudio presenta los resultados parciales de tesis de doctorado, realizada en el per&#237;odo descrito, bas&#225;ndose en una muestra de conveniencia.</p>
      <p>Fueron estudiados pacientes con diagn&#243;stico de miocardiopat&#237;a de etiolog&#237;as no isqu&#233;mica que llenasen los siguientes criterios:</p>
      <disp-quote>
        <p>1. Edad entre 18 y 75 a&#241;os;</p>
        <p>2. Tratamiento medicamentoso optimizado en la dosis m&#225;xima tolerada por el paciente por al menos un mes antes de la inclusi&#243;n en el estudio;</p>
        <p>3. Ritmo sinusal;</p>
        <p>4. QRS <underline>&gt;</underline> 120 ms al ECG de 12 derivaciones;</p>
        <p>5. FEVI &lt; 0,35 (medida al ecocardiograma bidimensional por el m&#233;todo de Simpson);</p>
        <p>6. Di&#225;metro diast&#243;lico final del ventr&#237;culo izquierdo (DDVE) &gt; 55 mm;</p>
        <p>7. Presencia de se&#241;ales y s&#237;ntomas de IC clase funcional (CF) III o IV (NYHA).</p>
      </disp-quote>
      <p>Los pacientes con edad mayor de 40 a&#241;os y factores de riesgo para enfermedad arterial coronaria fueron sometidos a la realizaci&#243;n de cineangiocoronariograf&#237;a para exclusi&#243;n de etiolog&#237;a isqu&#233;mica.</p>
      <p>Fueron considerados criterios de exclusi&#243;n: 1) imagen ecocardiogr&#225;fica inadecuada al an&#225;lisis tridimensional; el bloque del examen tridimensional fue considerado inadecuado para el an&#225;lisis cuando dos o m&#225;s segmentos no fueron visibilizados; 2) presencia de artefactos de translaci&#243;n card&#237;aca; 3) fibrilaci&#243;n atrial o de gran irregularidad del ritmo card&#237;aco pre-TRC; 4) pacientes imposibilitados de permanecer en peque&#241;o per&#237;odo de apnea (15 a 20 segundos) para adquisici&#243;n de las im&#225;genes ecocardiogr&#225;ficas tridimensionales; 5) muerte antes de completar por lo menos la primera reevaluaci&#243;n (a los tres meses despu&#233;s de TRC).</p>
      <p>Los pacientes que llenaron los criterios de inclusi&#243;n fueron encaminados al implante de marcapasos atriobiventricular (MPaBiv). Antes del alta hospitalaria, los pacientes fueron sometidos la evaluaci&#243;n ecocardiogr&#225;fica, para programaci&#243;n del Intervalo Atrioventricular (IAV) &#243;ptimo, por medio de la f&#243;rmula de Ritter<sup>7,8</sup>.</p>
      <p>Despu&#233;s del alta hospitalaria, la programaci&#243;n electr&#243;nica del MPaBiv fue reevaluada en el d&#233;cimo d&#237;a despu&#233;s de implante del marcapasos y, despu&#233;s de un y, tambi&#233;n, tres meses del implante, de acuerdo con la rutina de la Unidade Cl&#237;nica de Arritmia e Estimula&#231;&#227;o Card&#237;aca Artificial do InCor. El objetivo de esas evaluaciones fue garantizar el funcionamiento adecuado de los MPaBiv, en cada paciente.</p>
      <p>Fueron realizados ECG, evaluaci&#243;n cl&#237;nica, ecocardiograma bidimensional (2D), y tridimensional (3D) antes, tres y seis meses despu&#233;s de la TRC. Fueron evaluados los siguientes par&#225;metros: vol&#250;menes del ventr&#237;culo izquierdo (diast&#243;lico -VDVI, y sist&#243;lico - VSVI), fracci&#243;n de eyecci&#243;n ventricular izquierda (FEVI) y masa ventricular izquierda.</p>
      <p>Fueron evaluados los bloques volum&#233;tricos de ocho pacientes, incluidos en el protocolo, para an&#225;lisis de la variaci&#243;n intra y interobservador. Fueron evaluadas las siguientes variables: volumen diast&#243;lico y sist&#243;lico del ventr&#237;culo izquierdo, fracci&#243;n de eyecci&#243;n ventricular izquierda, obtenidos por el an&#225;lisis tridimensional. Para el an&#225;lisis intraobservador, fueron realizados dos an&#225;lisis del mismo bloque volum&#233;trico, por un mismo observador, con intervalo m&#237;nimo de un mes entre las lecturas.</p>
      <p>
        <bold>An&#225;lisis cl&#237;nico</bold>
      </p>
      <p>Todos los pacientes fueron sometidos a una evaluaci&#243;n cl&#237;nica compuesta por anamnesis, examen f&#237;sico, realizaci&#243;n de electrocardiograma de 12 derivaciones, y clasificaci&#243;n de la clase funcional seg&#250;n clasificaci&#243;n de la NYHA (<italic>New York Heart Association</italic>), adem&#225;s de evaluaci&#243;n de la calidad de vida por el "Minessota Living with Heart Failure Questionnaire" (MLHFQ).</p>
      <p>La clase funcional por la clasificaci&#243;n de la NYHA estratifica el grado de limitaci&#243;n impuesto por la IC en las actividades cotidianas del paciente. Esa clasificaci&#243;n, adem&#225;s de poseer car&#225;cter funcional, es tambi&#233;n una manera de evaluar la calidad de vida ante la IC<sup>2</sup>. Ya el MLHFQ est&#225; compuesto por 21 preguntas que eval&#250;an como el paciente percibe los efectos de la enfermedad y de su tratamiento en su vida diaria. Las cuestiones enfocan s&#237;ntomas como disnea, fatiga, edema, as&#237; como el estado psicol&#243;gico y el impacto de la enfermedad en la rutina diaria y laboral<sup>9</sup>.</p>
      <p>
        <bold>An&#225;lisis ecocardiogr&#225;fico</bold>
      </p>
      <p>Los estudios ecocardiogr&#225;ficos fueron realizados con el equipamiento iE33 Philips Medical Systems, Andover, MA, EUA. Fueron realizados los estudios ecocardiogr&#225;ficos bidimensional, an&#225;lisis de flujos card&#237;acos por el estudio Doppler y evaluaci&#243;n tridimensional en tiempo real. Las im&#225;genes fueron adquiridas en los planos paraesternal longitudinal de c&#225;maras izquierdas, transversal y apical 2, 3 y 4 c&#225;maras, de acuerdo con estandarizaci&#243;n de la Sociedad Americana de Ecocardiograf&#237;a<sup>10</sup>.</p>
      <p>
        <bold>An&#225;lisis bidimensional</bold>
      </p>
      <p>Fueron evaluados los siguientes par&#225;metros en los estudios ecocardiogr&#225;ficos: 1) di&#225;metro diast&#243;lico del ventr&#237;culo izquierdo y di&#225;metro sist&#243;lico del ventr&#237;culo izquierdo en proyecci&#243;n paraesternal longitudinal de c&#225;maras izquierdas; 2) volumen diast&#243;lico final del ventr&#237;culo izquierdo (VDVI) (m&#233;todo de Simpson); 3) volumen sist&#243;lico final del ventr&#237;culo izquierdo (VSVI) (m&#233;todo de Simpson); 4) FEVI (m&#233;todo de Simpson); 5) evaluaci&#243;n del flujo mitral para el an&#225;lisis de la di&#225;stole ventricular con el empleo del estudio Doppler puls&#225;til.</p>
      <p>
        <bold>An&#225;lisis tridimensional</bold>
      </p>
      <p>Los pacientes fueron posicionados en dec&#250;bito lateral izquierdo y fue utilizado transductor matricial X3, compatible con el equipamiento iE33, Philips Medical Systems. Las im&#225;genes tridimensionales, en tiempo real, fueron adquiridas en apnea espiratoria (15 a 20 segundos), con la observaci&#243;n del ciclo card&#237;aco a partir del registro electrocardiogr&#225;fico. Para la evaluaci&#243;n de los vol&#250;menes ventriculares y FEVI, los ajustes de aumento y compresi&#243;n fueron realizados de forma de permitir la obtenci&#243;n de im&#225;genes de buena calidad t&#233;cnica y identificaci&#243;n clara de los bordes endoc&#225;rdicos.</p>
      <p>La obtenci&#243;n del bloque volum&#233;trico (<italic>Full Volumen</italic>) fue hecha a partir de la adquisici&#243;n de cuatro peque&#241;os subvol&#250;menes, en ciclos card&#237;acos consecutivos, que, combinados, proveen un bloque piramidal de mayor volumen (110&#186;x 100&#186;). En cada adquisici&#243;n, los ajustes fueron hechos de modo que la totalidad del volumen ventricular izquierdo estuviese contenida en el bloque evaluado.</p>
      <p>Los VDVI, VSVI, y FEVI fueron evaluados, posteriormente, en estaci&#243;n de trabajo equipada con programa espec&#237;fico (Q-Lab, versiones 5.0. y 6.0., Philips Medical System, Andover, MA, EUA) por un algoritmo semiautom&#225;tico para la identificaci&#243;n de los bordes endoc&#225;rdicos. Ese programa provee, para cada cuadro adquirido, la visi&#243;n de los planos apical cuatro c&#225;maras, apical dos c&#225;maras y transversal. Para la reconstrucci&#243;n volum&#233;trica del VI, son identificados cinco puntos de referencia. A partir de esos puntos de referencia, son identificados los bordes endoc&#225;rdicos para el c&#225;lculo autom&#225;tico de VDVI, VSVI y FEVI. En los casos en que la detecci&#243;n autom&#225;tica present&#243; calidad sub&#243;ptima (falla en la identificaci&#243;n de los bordes endoc&#225;rdicos), fue realizada edici&#243;n de las im&#225;genes.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>El an&#225;lisis estad&#237;stico fue realizado para las variables cuantitativas continuas, por el c&#225;lculo de los valores m&#237;nimos, m&#225;ximos, medias y desv&#237;os-est&#225;ndar. Las variables cualitativas fueron presentadas en n&#250;meros absolutos, y calculadas las frecuencias absolutas y relativas (porcentaje).</p>
      <p>La comparaci&#243;n entre los par&#225;metros medidos por la ecocardiograf&#237;a bidimensional y tridimensional fue efectuada con el empleo de tests de regresi&#243;n lineal y correlaci&#243;n de Pearson (r). Fue realizado el an&#225;lisis de la variaci&#243;n intraobservador y interobservador de las medidas de los vol&#250;menes diast&#243;lico y sist&#243;lico del ventr&#237;culo izquierdo, fracci&#243;n de eyecci&#243;n ventricular izquierda, por medio del c&#225;lculo del coeficiente de correlaci&#243;n de concordancia.</p>
      <p>Fueron utilizados el Excel (2007), para la tabulaci&#243;n y organizaci&#243;n de los resultados, y un programa computacional para realizaci&#243;n del an&#225;lisis estad&#237;stico (SPSS versi&#243;n 13.0, Chicago, IL, EUA).</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Fueron evaluados 63 pacientes que llenaron los criterios de inclusi&#243;n en el per&#237;odo de 1/1/2007 a 1/6/2009. Este trabajo presenta parte de los resultados de tesis de doctorado (1/6/2006 a 18/6/2010), y los pacientes fueron seleccionados en el per&#237;odo de colecta de los datos para la tesis. De los 63 pacientes evaluados en el per&#237;odo, apenas 35 fueron encaminados a la TRC. De esos, ocho pacientes evolucionaron a &#243;bito antes de la primera reevaluaci&#243;n y fueron excluidos del an&#225;lisis, una vez que el objetivo del estudio era la evaluaci&#243;n del remodelado reverso.</p>
      <p>De los ocho &#243;bitos que ocurrieron antes de la primera reevaluaci&#243;n a los tres meses: un paciente necesit&#243; transplante card&#237;aco, evolucionando a &#243;bito despu&#233;s del transplante por complicaciones infecciosas; un paciente present&#243; parada cardiorrespiratoria (AESP - actividad el&#233;ctrica sin pulso) en el centro quir&#250;rgico, siendo reanimado con &#233;xito y transferido para UTI despu&#233;s del procedimiento, sin embargo falleci&#243; por shock cardiog&#233;nico; un paciente falleci&#243; por shock s&#233;ptico, secundario a infecci&#243;n del bolsillo del marcapasos; cinco pacientes fallecieron por insuficiencia card&#237;aca congestiva refractaria. La decisi&#243;n de encaminar el paciente a la TRC fue realizada, en conjunto, por los equipos de marcapasos e ICC del InCor.</p>
      <p>As&#237;, durante el per&#237;odo del estudio, fueron evaluados 35 pacientes sometidos a implante de MPaBiv. Ocurrieron ocho &#243;bitos, antes de los tres meses de reevaluaci&#243;n. De los 27 pacientes restantes, dos fueron excluidos por imagen ecocardiogr&#225;fica inadecuada, y una paciente rechaz&#243; la realizaci&#243;n de los ex&#225;menes de control, despu&#233;s de la TRC. De esa forma, 24 pacientes realizaron reevaluaci&#243;n antes, tres y seis meses despu&#233;s de la TRC (<xref ref-type="fig" rid="es_a04fig01-body2">figura 1</xref>). Todos los pacientes concordaron en participar del estudio y firmaron el T&#233;rmino de Consentimiento Libre y Aclarado.</p>
      <p content-type="asset">
        <fig id="es_a04fig01-body2">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf01-es.jpg"/></fig>
      </p>
      <p>La media et&#225;rea de los 27 pacientes analizados fue de 58,9 &#177; 9,7 a&#241;os, siendo 10/27 (37%) de los pacientes del sexo masculino y 17/27 (63%) del sexo femenino. La etiolog&#237;a de la miocardiopat&#237;a fue idiop&#225;tica, en la mayor&#237;a de los pacientes (24/27 pacientes; 89%), y chag&#225;sica en 3/27 pacientes (11%). La mayor&#237;a de los pacientes (21/27 pacientes; 77,8%) era portadora de hipertensi&#243;n arterial sist&#233;mica, mientras que 6/27 pacientes (22,2%) presentaban antecedente de diabetes mellitus (<xref ref-type="table" rid="tab1-body2">tab. 1</xref>).</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gt01-es.jpg"/></table-wrap>
      <p>En relaci&#243;n al tratamiento medicamentoso, 26/27 pacientes (96,3%) estaban en uso de inhibidores de la enzima de conversi&#243;n de la angiotensina (iECAs) o bloqueadores del receptor de la angiotensina II (BRAs); 26/27 pacientes (96,3%), en uso de betabloqueantes y diur&#233;ticos; 25/27 pacientes (92,3%), en uso de espironolactona; y 16/27 pacientes (59,3%), en uso de digoxina. El tratamiento fue mantenido, sin alteraciones, durante todo el per&#237;odo de seguimiento (<xref ref-type="table" rid="tab1-body2">tab. 1</xref>).</p>
      <p>Con relaci&#243;n a la evoluci&#243;n cl&#237;nica, despu&#233;s de tres meses de la TRC, hubo mejora de la CF (NYHA), p &lt; 0,001, de por lo menos un grado en 18/24 (75%) de los pacientes y manutenci&#243;n de la CF en 6/24 (25%) de los pacientes. A los seis meses despu&#233;s de la TRC, 19/24 (79%) mantuvieron la mejora en la CF (NYHA) y 5/24 (21%) no presentaron alteraciones de la CF, p &lt; 0,001 (<xref ref-type="fig" rid="es_a04fig02-body2">Fig. 2A</xref>). Tambi&#233;n fue evidenciada mejora de la calidad de vida, evaluada por el escore de Minnesota (MLHFQ), tres meses despu&#233;s de TRC, en 21/24 (88%) de los pacientes, empeoramiento 1/24 (4%), y 2/24 (8%) de los pacientes no presentaron alteraciones (p &lt; 0,001). A los seis meses despu&#233;s de la TRC, 20/24 (83%) de los pacientes presentaron mejora del MLHFQ, 3/24 (13%) presentaron empeoramiento y 1/24 (4%) paciente no present&#243; alteraciones, p &lt; 0,001 (<xref ref-type="fig" rid="es_a04fig02-body2">Fig. 2B</xref>).</p>
      <p content-type="html"><fig id="es_a04fig02-body2"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/sHdhBWFVYYKJCBV7qz6ZWKD/99bd1390153fceba9d4aab6abd87352517200359.jpg"/><graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf02-es.jpg"/></fig>&#13;
&#160;&#13;
</p>
      <p>El an&#225;lisis de los vol&#250;menes ventriculares por el modo bidimensional, por medio del m&#233;todo de Simpson (VDVI: 283 &#177; 117 ml; VSVI: 219 &#177; 93 ml en el momento basal), revel&#243; reducci&#243;n de los vol&#250;menes ventriculares diast&#243;lico y sist&#243;lico del ventr&#237;culo izquierdo (VDVI: 262 &#177; 124 ml, p = 0,018; VSVI: 196 &#177; 105 ml, p = 0,007) despu&#233;s de tres meses de la TRC. Esa reducci&#243;n se mantuvo en la evaluaci&#243;n despu&#233;s de seis meses de la TRC (VDVI: 256 &#177; 137 ml, p = 0,038; VSVI: 185 &#177; 114 ml, p = 0,027) (<xref ref-type="table" rid="es_a04tab02-body2">tab. 2</xref>; <xref ref-type="fig" rid="es_a04fig03-body2">Fig. 3</xref> y <xref ref-type="fig" rid="es_a04fig04-body2">4</xref>).</p>
      <p content-type="asset">
        <table-wrap id="es_a04tab02-body2">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gt02-es.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <fig id="es_a04fig03-body2">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf03-es.jpg"/></fig>
      </p>
      <p content-type="asset">
        <fig id="es_a04fig04-body2">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf04-es.jpg"/></fig>
      </p>
      <p>La fracci&#243;n de eyecci&#243;n ventricular izquierda (0,23 &#177; 0,05), evaluada por el m&#233;todo de Simpson, tambi&#233;n present&#243; mejora a los tres meses (0,28 &#177; 0,07, p = 0,028) despu&#233;s de TRC, y la cual se mantuvo a los seis meses (0,28 &#177; 0,10, p = 0,006), despu&#233;s de TRC (<xref ref-type="table" rid="es_a04tab02-body2">tab. 2</xref>) (<xref ref-type="fig" rid="es_a04fig05-body2">Fig. 5</xref>).</p>
      <p content-type="asset">
        <fig id="es_a04fig05-body2">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf05-es.jpg"/></fig>
      </p>
      <p>El an&#225;lisis por el Eco 3D evidenci&#243; medias y desv&#237;oest&#225;ndar de los vol&#250;menes ventriculares diast&#243;lico y sist&#243;lico de 252 &#177; 105 ml y 194 &#177; 86 ml, respectivamente, en el momento basal. Despu&#233;s de la TRC, hubo reducci&#243;n no significativa de los vol&#250;menes ventriculares, evaluados al Eco 3D. A los tres meses despu&#233;s de TRC, hubo reducci&#243;n de 25 ml (10%) de la media de los valores de VDVI y de 26 ml (13%) de la media de los valores de VSVI, en relaci&#243;n al momento basal (VDVI: 227 &#177; 113 ml, p = 0,187; VSVI: 168 &#177; 95 ml, p = 0,065). A los seis meses despu&#233;s de TRC, la reducci&#243;n del VDVI fue de 13 ml (5%) y de 6 ml (6%) del VSVI, en relaci&#243;n al momento basal (VDVI: 239 + 129 ml, p = 0,163; VSVI: 183 + 115 ml, p = 0,347) (<xref ref-type="table" rid="es_a04tab02-body2">tab. 2</xref>; <xref ref-type="fig" rid="es_a04fig02-body2">fig. 2</xref> y <xref ref-type="fig" rid="es_a04fig03-body2">3</xref>). Con relaci&#243;n a la FEVI, hubo mejora (21,7%), en relaci&#243;n al momento basal (FEVI: 0,23 &#177; 0,05), evidenciada a los tres meses, despu&#233;s de TRC (FEVI: 0,28 &#177; 0,07, p = 0,008) y que se mantuvo a los seis meses (FEVI: 0,28 &#177; 0,10; p = 0,033) (<xref ref-type="table" rid="es_a04tab02-body2">tab. 2</xref>; <xref ref-type="fig" rid="es_a04fig05-body2">Fig. 5</xref>).</p>
      <p>No hubo variaci&#243;n de la masa ventricular izquierda a los tres meses (p = 0,511 por el Eco 3D) y seis meses (p = 0,706 al Eco 2D, p = 0,479 al Eco 3D), despu&#233;s de la TRC (<xref ref-type="table" rid="es_a04tab02-body2">tab. 2</xref>).</p>
      <p>En el momento basal, la correlaci&#243;n entre los m&#233;todos fue de 0,96 para evaluaci&#243;n del VDVI, 0,95 para evaluaci&#243;n del VSVI, 0,87 para FEVI y 0,72 para masa del VI. Despu&#233;s de tres meses de la TRC, la correlaci&#243;n entre el Eco 2D y 3D para an&#225;lisis del VDVI fue de 0,96, 0,95 para VSVI, 0,95 para FEVI y 0,77 para masa del VI. Despu&#233;s de seis meses de la TRC, la correlaci&#243;n entre el Eco 2D y 3D para an&#225;lisis del VDVI fue de 0,98, 0,91 para VSVI, 0,96 para FEVI y 0,85 para masa del VI (<xref ref-type="fig" rid="es_a04fig06-body2">Fig. 6</xref> y <xref ref-type="fig" rid="es_a04fig07-body2">7</xref>).</p>
      <p content-type="asset">
        <fig id="es_a04fig06-body2">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf06-es.jpg"/></fig>
      </p>
      <p content-type="asset">
        <fig id="es_a04fig07-body2">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf07-es.jpg"/></fig>
      </p>
      <p>Con relaci&#243;n a la evaluaci&#243;n de la variaci&#243;n intra y interobservador por el Eco 3D, el coeficiente de correlaci&#243;n de concordancia (CCC) del an&#225;lisis del VDVI intraobservador fue de 0,95 (95% Intervalo de confianza: 0,80 a 0,99) y el del interobservador fue de 0,95 (95% Intervalo de confianza: 0,77 a 0,99). EL CCC del an&#225;lisis del VSVI intraobservador fue de 0,97 (95% Intervalo de confianza: 0,86 a 0,99) y el del interobservador fue de 0,95 (95% Intervalo de confianza: 0,81 a 0,99). El CCC del an&#225;lisis de la FEVI intraobservador fue de 0,97 (95% Intervalo de confianza: 0,86 a 0,99) y el del interobservador fue de 0,92 (95% Intervalo de confianza: 0,71 a 0,98).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>En pacientes con IC avanzada, la dilataci&#243;n ventricular izquierda importante es considerada factor independiente de peor pron&#243;stico<sup>11</sup>. Pacientes con miocardiopat&#237;a dilatada idiop&#225;tica y dilataci&#243;n ventricular importante presentan disminuci&#243;n de la reserva de flujo coronario, detectada en estudios de perfusi&#243;n mioc&#225;rdica con t&#233;cnicas de medicina nuclear y por la ecocardiograf&#237;a bajo estr&#233;s farmacol&#243;gico con dipiridamol<sup>12-14</sup>. Esos hallazgos est&#225;n asociados al mayor estr&#233;s sist&#243;lico en la pared ventricular izquierda y a &#225;reas de consumo anormal de ox&#237;geno sugiriendo la presencia de isquemia y peor pron&#243;stico en estos pacientes.</p>
      <p>Por lo tanto, pacientes con IC grave y dilataci&#243;n ventricular importante, evidenciada por el aumento del DDVI y de los vol&#250;menes ventriculares, pueden presentar peor respuesta a la TRC en raz&#243;n de menor reserva de flujo coronario y de presencia de &#225;reas con est&#225;ndar anormal del consumo de ox&#237;geno. La evaluaci&#243;n del grado de dilataci&#243;n ventricular analizada por la ecocardiograf&#237;a 2D y 3D en el momento basal provee informaciones importantes respecto a la evoluci&#243;n de los pacientes despu&#233;s de la TRC. As&#237;, se sabe la importancia de la evaluaci&#243;n de los VSVI y VDVI antes de la TRC.</p>
      <p>En estudio de Ant&#243;nio et al<sup>15</sup>, pacientes en fases m&#225;s informaciones predictivas importantes respecto a los precoces de miocardiopat&#237;a y menores alteraciones en la desenlaces cl&#237;nicos en la evoluci&#243;n natural de la enfermedad, geometr&#237;a ventricular presentaron mayor probabilidad de seg&#250;n lo demostrado inicialmente por Yu et al<sup>16 </sup>y confirmado respuesta con la TRC. Adicionalmente, la evaluaci&#243;n de en estudio reciente de Ypenburg et al<sup>17</sup>. Datos respecto las alteraciones volum&#233;tricas despu&#233;s de la TRC provee a la utilizaci&#243;n de terapias farmacol&#243;gicas enfatizan la importancia del remodelado reverso ventricular izquierdo en el pron&#243;stico a largo plazo, volviendo, de esa forma, esa variable muy &#250;til como marcador de mejora cl&#237;nica. En el estudio de Ypenburg et al<sup>17</sup>, la extensi&#243;n del remodelado reverso present&#243; aun correlaci&#243;n con el pron&#243;stico a largo plazo: cuanto mayor la tasa de remodelado reverso, mejor la evoluci&#243;n cl&#237;nica y viceversa.</p>
      <p>El valor de la ecocardiograf&#237;a tridimensional en la evaluaci&#243;n de los vol&#250;menes ventriculares, fracci&#243;n de eyecci&#243;n y masa ventricular izquierda ya fue comprobado en diversos estudios, con excelente correlaci&#243;n de resultados cuando fue comparado a la resonancia magn&#233;tica card&#237;aca<sup>5,6</sup>. La adquisici&#243;n de los bloques volum&#233;tricos, por medio del Eco 3D, para evaluaci&#243;n de esos par&#225;metros, puede ser realizada r&#225;pidamente, con la utilizaci&#243;n de un transductor matricial, y la cuantificaci&#243;n de los datos, por un operador entrenado y experimentado, dura en promedio de seis a ocho minutos<sup>18,19</sup>.</p>
      <p>De ese modo, el Eco 3D se constituye en una herramienta muy &#250;til en la evaluaci&#243;n ecocardiogr&#225;fica, aumentando la precisi&#243;n de los c&#225;lculos de los vol&#250;menes, FEVI y masa ventricular izquierda, sin aumentar de manera significativa la duraci&#243;n del examen. Sin embargo, actualmente, el Eco 3D aun no est&#225; ampliamente disponible, requiere equipamientos y programas computacionales espec&#237;ficos para la cuantificaci&#243;n de los datos, adem&#225;s de exigir entrenamiento adecuado para la adquisici&#243;n de bloques volum&#233;tricos de buena calidad t&#233;cnica.</p>
      <p>La ecocardiograf&#237;a bidimensional, por su vez, es ampliamente disponible y ha sido el m&#233;todo m&#225;s utilizado en la evaluaci&#243;n de pacientes candidatos a la TRC y en la evaluaci&#243;n de la respuesta despu&#233;s de esa terap&#233;utica.</p>
      <p>En este estudio, fue comparada la evaluaci&#243;n de los datos respecto a la morfolog&#237;a y funci&#243;n ventricular izquierda por el Eco 2D y 3D, en el momento pre-TRC, lo que auxilia en la selecci&#243;n de los candidatos la TRC, y tres y seis meses despu&#233;s de la TRC, a fin de evaluar la respuesta al tratamiento.</p>
      <p>La evaluaci&#243;n de los vol&#250;menes ventriculares despu&#233;s de la TRC es importante en el reconocimiento del remodelado reverso ventricular izquierdo, definido como reducci&#243;n de los vol&#250;menes diast&#243;lico y sist&#243;lico del ventr&#237;culo izquierdo y mejora de la FEVI. La identificaci&#243;n del remodelado reverso por la ecocardiograf&#237;a tiene importancia pron&#243;stica, una vez que la respuesta volum&#233;trica ha presentado mejor valor predictivo de sobrevida libre de eventos y mortalidad, cuando fue comparada a la respuesta cl&#237;nica evaluada por la mejora de la clase funcional (NYHA) y de calidad de vida<sup>16,20</sup>. Una vez comprobada la superioridad del Eco 3D, en relaci&#243;n al Eco 2D, en la evaluaci&#243;n de los vol&#250;menes ventriculares, masa y FEVI, es fundamental evaluar la concordancia entre esas dos t&#233;cnicas, pues el Eco 2D es el m&#233;todo m&#225;s utilizado en pacientes sometidos a TRC.</p>
      <p>Los vol&#250;menes ventriculares (VDVI y VSVI) evaluados tanto por el m&#233;todo de Simpson como por el Eco 3D proveen informaciones adicionales a la selecci&#243;n de los pacientes y a la tasa de respuesta a la TRC. La mejora y el grado de mejora de la FEVI evaluada despu&#233;s de la TRC presentan buena correlaci&#243;n con la mejora en la evoluci&#243;n cl&#237;nica de los pacientes sometidos a la TRC. Seg&#250;n Di Biase et al<sup>21</sup>, el aumento de seis puntos o m&#225;s en la FEVI a los tres meses despu&#233;s de la TRC presenta tasa alrededor de 66% libre de eventos en cinco a&#241;os de seguimiento.</p>
      <p>En este estudio, hubo mejora significativa de la FEVI evaluada por ambos m&#233;todos (Simpson y Eco 3D) tres meses despu&#233;s de la TRC y que se mantuvo a los seis meses de la TRC en la muestra total del estudio. Hubo aun excelente correlaci&#243;n entre los m&#233;todos para la medici&#243;n volum&#233;trica ventricular izquierda durante todas las fases del estudio, lo que demuestra la utilidad de la ecocardiograf&#237;a bidimensional en el control y evaluaci&#243;n del remodelado reverso de los pacientes sometidos la TRC, en cuanto el Eco 3D no es parte de la evaluaci&#243;n ecocardiogr&#225;fica en la pr&#225;ctica cl&#237;nica diaria.</p>
      <p>La evaluaci&#243;n de la masa del VI por el Eco 3D es superior al Eco 2D, cuando es comparada a la RMC. Es importante notar que a pesar de la buena correlaci&#243;n entre los Ecos 2D y 3D para evaluaci&#243;n de la masa, el Eco 3D es m&#225;s preciso, justificando su uso cuando est&#225; disponible. Sin embargo, a pesar de la superioridad del Eco 3D para evaluaci&#243;n de los vol&#250;menes, masa y funci&#243;n ventricular izquierda en relaci&#243;n al Eco 2D (cuando son comparados a la RMC, que es actualmente el m&#233;todo est&#225;ndar de referencia para esos an&#225;lisis), el Eco 2D es el m&#233;todo m&#225;s utilizado en la practica cl&#237;nica por su disponibilidad y costo. De esa forma, los resultados de este estudio, al demostrar la excelente correlaci&#243;n entre los m&#233;todos (Ecos 2D y 3D), vuelve el Eco 2D un m&#233;todo confiable para la evaluaci&#243;n del remodelado reverso despu&#233;s de la TRC.</p>
      <p>
        <bold>Limitaciones del estudio</bold>
      </p>
      <p>Hubo discreto aumento del volumen ventricular entre los tres y seis meses despu&#233;s de la TRC, detectado al Eco 3D. Creemos que ese hallazgo aun sea consecuencia de las limitaciones inherentes a la tecnolog&#237;a actual de los equipamientos de Eco 3D. Los pacientes incluidos en este estudio presentaban valores muy altos de DDVI y dilataci&#243;n importante de los vol&#250;menes ventriculares, lo que dificult&#243; la inclusi&#243;n de todo el ventr&#237;culo izquierdo en la adquisici&#243;n del bloque tridimensional. A pesar de haber sido excluidos los bloques con imposibilidad de evaluaci&#243;n de dos o m&#225;s segmentos mioc&#225;rdicos, la dificultad en la evaluaci&#243;n de la pared lateral al plano coronal y de las paredes inferior y anterior, en el plano sagital, pueden haber limitado el c&#225;lculo de los vol&#250;menes ventriculares izquierdos al Eco 3D. Adem&#225;s de eso, limitaciones en el grado de abertura del haz ultras&#243;nico y el bajo <italic>frame rate </italic>(20 a 30 vol&#250;menes/segundo) del Eco 3D, tambi&#233;n, pueden haber resultado en la diferencia no significativa entre los vol&#250;menes ventriculares izquierdos de los GI y GII, antes de la TRC.</p>
      <p>El Eco 3D, a pesar de estar disponible hace cerca de cuatro d&#233;cadas, aun no lleg&#243; a su formato definitivo y presenta limitaciones f&#237;sicas y en su formato de presentaci&#243;n en diferentes programas de adquisici&#243;n, lectura y de interpretaci&#243;n. El desarrollo del Eco 3D permitir&#225; sin duda trabajar en un futuro pr&#243;ximo con pacientes que presenten grandes dilataciones ventriculares y que presenten acentuada variaci&#243;n de ritmo card&#237;aco (fibrilaci&#243;n atrial) y ritmo respiratorio.</p>
      <p>Otra limitaci&#243;n se refiere a la no utilizaci&#243;n de la resonancia magn&#233;tica card&#237;aca en la evaluaci&#243;n de los vol&#250;menes ventriculares y FEVI para comparaci&#243;n con los Ecos 2D y 3D, una vez que ese es el m&#233;todo considerado est&#225;ndar de referencia para esa finalidad.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>En este estudio, fue observada reducci&#243;n de los vol&#250;menes diast&#243;lico y sist&#243;lico del ventr&#237;culo izquierdo, adem&#225;s de mejora de la FEVI despu&#233;s de la TRC. Hubo excelente correlaci&#243;n entre los Ecos 2D y 3D para evaluaci&#243;n de los vol&#250;menes ventriculares y fracci&#243;n de eyecci&#243;n ventricular izquierda, y buena correlaci&#243;n entre los m&#233;todos para evaluaci&#243;n de la masa ventricular izquierda antes y despu&#233;s de la TRC.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>SOCEPS financi&#243; el presente estudio de julio de 2009 a julio de 2010.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Viviane Tiemi Hotta, por la Faculdade de Medicina da USP.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Comparison between 2D and 3D echocardiography in the evaluation of reverse remodeling after CRT</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Echocardiography is a useful method for screening and assessing response to cardiac resynchronization therapy (CRT). 3D echocardiography has already established its role in the evaluation of ventricular volumes and ejection fraction (LVEF) with excellent correlation of results when compared with MRI. OBJECTIVE: To compare the evaluation of ventricular volumes (LVDV, LVSV), LVEF, and LV mass before and after CRT by 2D echocardiography and three-dimensional echocardiography. METHODS: We evaluated 24 patients with HF FCIIIouIV (NYHA), sinus rhythm QRS &gt; 150 ms, during an optimized therapy for HF undergoing CRT. We conducted electrocardiogram (ECG), clinical evaluation, 2D and 3D echocardiography before, three and six months after CRT. The comparison between the techniques was performed using Pearson's correlation (r). Results: At baseline, the correlation between methods was 0.96 for evaluation of LVDV, 0.95 for evaluation of LVSV, 0.87 for LVEF and 0.72 for LV mass. After three months of CRT, the correlation between methods for analysis of LVDV was 0.96, 0.95 for LVSV, 0.95 for LVEF, and 0.77 for LV mass. After six months of CRT, the correlation between 2D and 3D echocardiography for analysis of LVDV was 0.98, 0.91 for LVSV, 0.96 for LVEF, and 0.85 for LV mass. CONCLUSION: This study reported was a reduction of LVDV, LVSV, besides improvement in LVEF after CRT. There was an excellent correlation between the 2D and 3D echocardiography for evaluation of ventricular volumes and LVEF, and a good correlation between methods for evaluation of left ventricular mass before and after CRT.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Echocardiography</kwd>
        <kwd>echocardiography, three-dimensional</kwd>
        <kwd>stroke volume</kwd>
        <kwd>ventricular dysfunction, left</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="ab-body3">
          <label>
            <bold>Comparison between 2D and 3D echocardiography in the evaluation of reverse remodeling after CRT</bold>
          </label>
          <p>
            <bold>Viviane Tiemi Hotta; Martino Martinelli Filho; Charles Mady; Wilson Mathias Jr.; Marcelo L.C. Vieira</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) da Faculdade de Medicina da Universidade de S&#227;o Paulo, Fleury Medicina e Sa&#250;de, Hospital Israelita Albert Einstein, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Echocardiography is a useful method for screening and assessing response to cardiac resynchronization therapy (CRT). 3D echocardiography has already established its role in the evaluation of ventricular volumes and ejection fraction (LVEF) with excellent correlation of results when compared with MRI.</p>
      <p><bold>OBJECTIVE:</bold> To compare the evaluation of ventricular volumes (LVDV, LVSV), LVEF, and LV mass before and after CRT by 2D echocardiography and three-dimensional echocardiography.</p>
      <p><bold>METHODS:</bold> We evaluated 24 patients with HF FCIIIouIV (NYHA), sinus rhythm QRS <underline>&gt;</underline> 150 ms, during an optimized therapy for HF undergoing CRT. We conducted electrocardiogram (ECG), clinical evaluation, 2D and 3D echocardiography before, three and six months after CRT. The comparison between the techniques was performed using Pearson's correlation (r).</p>
      <p><bold>RESULTS:</bold> At baseline, the correlation between methods was 0.96 for evaluation of LVDV, 0.95 for evaluation of LVSV, 0.87 for LVEF and 0.72 for LV mass. After three months of CRT, the correlation between methods for analysis of LVDV was 0.96, 0.95 for LVSV, 0.95 for LVEF, and 0.77 for LV mass. After six months of CRT, the correlation between 2D and 3D echocardiography for analysis of LVDV was 0.98, 0.91 for LVSV, 0.96 for LVEF, and 0.85 for LV mass.</p>
      <p><bold>CONCLUSION:</bold> This study reported was a reduction of LVDV, LVSV, besides improvement in LVEF after CRT. There was an excellent correlation between the 2D and 3D echocardiography for evaluation of ventricular volumes and LVEF, and a good correlation between methods for evaluation of left ventricular mass before and after CRT.</p>
      <p><bold>Keywords:</bold> Echocardiography; echocardiography, three-dimensional; stroke volume; ventricular dysfunction, left.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Echocardiography is a useful method for screening and evaluating response to Cardiac Resynchronization Therapy (CRT) for patients with heart failure (HF) and severe ventricular conduction disturbance<sup>1-4</sup>. Three-dimensional echocardiography (3D echocardiography) already has its established role in the evaluation of ventricular volumes and left ventricular ejection fraction (LVEF) with excellent correlation of results compared to cardiac magnetic resonance<sup>5,6</sup>. Regarding the two-dimensional echocardiography (2D echocardiography), 3D echocardiography is closer to the real anatomy because of the absence of geometric inferences.</p>
      <p>Once the 2D echocardiography has increased availability and has been the most widely used method for monitoring these patients, this study demonstrated its correlation with 3D echocardiography in the evaluation of ventricular volumes (left ventricular end-diastolic volume and left ventricular end-systolic volume), ejection fraction and left ventricular mass before and after CRT.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>We conducted a prospective observational study from January 1, 2007 to June 1, 2009. The project was approved by the Scientific and Ethics Committee of InCor - HCFMUSP, by the Ethics Committee for Analysis of Research Projects (CAPPesq) of the Clinical Board of <italic>Hospital das Cl&#237;nicas da Universidade de S&#227;o Paulo</italic>. This study presents partial results of a doctoral thesis conducted in the period described based on a convenience sample.</p>
      <p>We studied patients diagnosed with cardiomyopathy of nonischemic etiology who fulfilled the following criteria:</p>
      <disp-quote>
        <p>1. Aged 18 to 75 years;</p>
        <p>2. Optimized drug therapy at maximum dose tolerated by the patient for at least one month before being included in the study;</p>
        <p>3. Sinus rhythm;</p>
        <p>4. QRS &gt; 120 ms on 12-lead ECG;</p>
        <p>5. LVEF &lt; 0.35 (measured by two-dimensional echocardiography by the Simpson's method);</p>
        <p>6. Left ventricular end-diastolic diameter (LVEDD) &gt; 55 mm;</p>
        <p>7. Presence of signs and symptoms of HF class III or IV (NYHA).</p>
      </disp-quote>
      <p>Patients older than 40 years with risk factors for coronary artery disease underwent coronary angiography to exclude ischemic etiology.</p>
      <p>Exclusion criteria were: 1) improper echocardiographic image for three-dimensional analysis; block of three-dimensional examination was considered improper for analysis when two or more segments were not viewed; 2) presence of cardiac translational artifacts; 3) atrial fibrillation or large irregular heart rhythm pre-CRT; 4) patients unable to remain in short period of apnea (15-20 seconds) for three-dimensional echocardiographic image acquisition; 5) death before completion of at least the first reassessment (at three months after CRT ).</p>
      <p>Patients who met the inclusion criteria were referred to the implantation of a biventricular pacemaker (BvPa). Before hospital discharge, patients underwent echocardiographic evaluation, to program optimal Atrioventricular Interval (AVI) through the Ritter's formula<sup>7,8</sup>.</p>
      <p>After discharge, the electronic programming of BvPa was reassessed on the tenth day after the pacemaker implantation and after one and three months after implantation, according to the routine of InCor's Clinical Unit of Arrhythmia and Cardiac Pacing. The purpose of these evaluations was to ensure the proper operation of BvPa in each patient.</p>
      <p>ECG, clinical evaluation, two-dimensional (2D) and three-dimensional (3D) echocardiography were performed before, three and six months after CRT. We evaluated the following parameters: left ventricular volumes (diastolic - LVDV, and systolic - LVSV), left ventricular ejection fraction (LVEF) and left ventricular mass.</p>
      <p>We evaluated the volumetric blocks of eight patients included in the protocol for the analysis of intra and interobserver variation. We evaluated the following variables: left ventricular diastolic and systolic volume, left ventricular ejection fraction, obtained by three-dimensional analysis. For the intraobserver analysis, two analyses of the same volumetric block were performed by the same observer with an interval of one month between readings.</p>
      <p>
        <bold>Clinical analysis</bold>
      </p>
      <p>All patients underwent a clinical evaluation consisting of history taking, physical examination, 12-lead electrocardiogram, and classification of functional class according to the NYHA (New York Heart Association), in addition to evaluating the quality of life using the Minnesota Living with Heart Failure (MLHF).</p>
      <p>The functional class by NYHA classification stratifies the degree of limitation imposed by the HF in the patient's daily activities. This classification has a functional nature and is also a way to evaluate the quality of life with HF<sup>2</sup>. The MLHF questionnaire consists of 21 questions that assess how the patient perceives the effects of the disease and treatment in their daily lives. The questions focus on symptoms such as dispnea, fatigue, edema, and the psychological status and impact of the disease on the daily and labor routine<sup>9</sup>.</p>
      <p>
        <bold>Echocardiography</bold>
      </p>
      <p>Echocardiographic studies were performed using the equipment IE33 Philips Medical Systems, Andover, MA, USA. Two-dimensional echocardiography, cardiac flow analysis by Doppler and real time three-dimensional evaluation were performed. The images were acquired on longitudinal paraesternal planes of 2, 3 and 4 left, lateral and apical chambers as standardized by the American Society of Echocardiography<sup>10</sup>.</p>
      <p>
        <bold>Two-dimensional analysis</bold>
      </p>
      <p>The following parameters were evaluated in echocardiographic studies: 1) left ventricular diastolic diameter and left ventricular systolic diameter in left-chamber longitudinal parasternal view; 2) left ventricular end-diastolic volume (VDVE) (Simpson's method); 3) left ventricular end-systolic volume (LVSV) (Simpson's method); 4) LVEF (Simpson's method); 5) evaluation of mitral flow for analysis of ventricular diastole with pulsed Doppler study.</p>
      <p>
        <bold>Three-dimensional analysis</bold>
      </p>
      <p>Patients were positioned in the left lateral position and an X3 matrix array transducer was used, compatible with the equipment IE33, Philips Medical Systems. Real time three-dimensional images were acquired in expiratory apnea (15-20 seconds) with observation of cardiac cycle from electrocardiographic recording. For the evaluation of ventricular volumes and LVEF, gain and compression adjustments were performed to allow imaging of good technical quality and clear identification of endocardial borders.</p>
      <p>Volumetric block (full volume) was made from the acquisition of four small subvolumes in consecutive cardiac cycles combined to provide a pyramidal block of greater volume (110&#186; x 100&#186;). In each acquisition, adjustments were made so that the entire left ventricular volume was contained in the block evaluated.</p>
      <p>LVDV, LVSV and LVEF were assessed later on a workstation equipped with a specific program (Q-Lab, versions 5.0. And 6.0., Philips Medical System, Andover, MA, USA) by a semiautomatic algorithm for identification of endocardial borders. This program provides, for every frame acquired, the view of four-chamber, two-chamber and cross-sectional apical planes. For the volumetric reconstruction of LV, five reference points are identified. From these reference points, endocardial borders are identified for the automatic calculation of LVDV, LVSV and LVEF. In cases where automatic detection showed suboptimal quality (lack of identification of endocardial borders) the images were edited.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Statistical analysis was performed for continuous quantitative variables, by calculating minimum, maximum, mean and standard deviations. Qualitative variables were presented as absolute numbers, and absolute and relative frequencies were calculated (percentage).</p>
      <p>The comparison between the parameters measured by two-dimensional and three-dimensional echocardiography was performed using linear regression and Pearson correlation (r) tests. We performed the analysis of intraobserver and interobserver variation between measurements of left ventricular diastolic and systolic volumes, left ventricular ejection fraction, by calculating the concordance correlation coefficient.</p>
      <p>We used Excel (2007) for the organization and tabulation of results, and a computer program for statistical analysis (SPSS version 13.0, Chicago, IL, USA).</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>We evaluated 63 patients who met the inclusion criteria from January 1, 2007 to June 1, 2009. This paper presents some results from a doctoral thesis (June 1, 2006 to June 18, 2010), and patients were selected during the data collection period for the thesis. Out of 63 patients evaluated in the period, only 35 were referred to CRT. Out of these, eight patients died before the first reevaluation and were excluded from the analysis, since the purpose of the study was the evaluation of reverse remodeling.</p>
      <p>Out of the eight deaths that occurred before the first reassessment at three months: one patient needed a heart transplant, dying after transplantation for infectious complications; one patient had a cardiac arrest (PEA - Pulseless Electrical Activity) in the operating room, being successfully resuscitated and transferred to the ICU after the procedure, but died of cardiogenic shock; one patient died of septic shock secondary to infection of pacemaker pocket; five patients died from refractory congestive heart failure. The decision to refer the patient to CRT was taken jointly by InCor's pacemaker and congestive heart failure teams.</p>
      <p>Thus, during the study period, we evaluated 35 patients who underwent implantation of BvPa. There were eight deaths before the three-month revaluation. Out of the 27 remaining patients, two were excluded for inadequate echocardiographic image, and one patient refused to perform examinations of monitoring after the CRT. Then, 24 patients underwent re-evaluation before and six months after CRT (flowchart 1). All patients agreed to participate in the study and signed a consent form.</p>
      <p>The average age of the 27 patients analyzed was 58.9 &#177; 9.7 years, of which 10/27 (37%) were male and 17/27 (63%) were female. The etiology of cardiomyopathy was idiopathic in most patients (24/27 patients; 89%), and Chagas disease in 3/27 patients (11%). Most patients (21/27 patients; 77.8%) were hypertensive, while 6/27 patients (22.2%) had a history of diabetes mellitus (<xref ref-type="table" rid="tab1-body3">Table 1</xref>).</p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gt01-en.jpg"/></table-wrap>
      <p>In relation to drug treatment, 26/27 patients (96.3%) were using angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs); 26/27 patients (96.3% ) were using beta-blockers and diuretics; 25/27 patients (92.3%) were on spironolactone; and 16/27 patients (59.3%) were using digoxin. The treatment was maintained unchanged throughout the follow-up period (<xref ref-type="table" rid="tab1-body3">Table 1</xref>).</p>
      <p>With respect to clinical progression after three months of CRT, there was improvement in FC (NYHA), p &lt; 0.001 of at least one grade in 18/24 (75%) of patients and maintenance of FC in 6/24 (25%) of patients. At six months after CRT, 19/24 (79%) showed improvement in FC (NYHA) and 5/24 (21%) showed no change in FC, p &lt; 0.001 (<xref ref-type="fig" rid="en_aop06511fig01-body3">Fig. 1A</xref>). Improved quality of life was measured by the Minnesota score (MLHFQ) three months after CRT in 21/24 (88%) of patients, worsening in 1/24 (4%), and 2/24 (8%) of patients with no changes (p &lt; 0.001). At six months after CRT, 20/24 (83%) of patients improved in MLHFQ, 3/24 (13%) had worsened and 1/24 (4%) patient presented no change, p &lt; 0.001 (<xref ref-type="fig" rid="en_aop06511fig01-body3">Fig. 1B</xref>).</p>
      <p content-type="html"><fig id="en_aop06511fig01-body3"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/sHdhBWFVYYKJCBV7qz6ZWKD/b6afa1531b39e35e014a1db6d1dcd1a389a8b82a.jpg"/><graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf01-en.jpg"/></fig>&#13;
&#160;&#13;
&#160;&#13;
</p>
      <p>The analysis of ventricular volumes by the two-dimensional mode, using the Simpson's method (LVDV: 283 &#177; 117 ml; LVSV: 219 &#177; 93 ml at baseline) revealed decreased left ventricular diastolic and systolic volumes (LVDV: 262 &#177; 124 ml, p = 0.018; LVSV: 196 &#177; 105 ml, p = 0.007) after three months of CRT. This reduction was maintained in the evaluation after six months of CRT (LVDV: 256 &#177; 137 ml, p = 0.038; LVSV: 185 &#177; 114 ml, p = 0.027) (<xref ref-type="table" rid="en_aop06511tab02-body3">Table 2</xref>, <xref ref-type="fig" rid="en_aop06511fig02-body3">Fig. 2</xref> and <xref ref-type="fig" rid="en_aop06511fig03-body3">3</xref>).</p>
      <p content-type="asset">
        <table-wrap id="en_aop06511tab02-body3">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gt02-en.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <fig id="en_aop06511fig02-body3">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf02-en.jpg"/></fig>
      </p>
      <p content-type="asset">
        <fig id="en_aop06511fig03-body3">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf03-en.jpg"/></fig>
      </p>
      <p>The left ventricular ejection fraction (0.23 &#177; 0.05), evaluated by Simpson's method, also showed improvement at three months (0.28 &#177; 0.07, p = 0.028) after CRT, which remained stable at six months (0.28 &#177; 0.10, p = 0.006), after CRT (<xref ref-type="table" rid="en_aop06511tab02-body3">Table 2</xref>) (<xref ref-type="fig" rid="en_aop06511fig04-body3">Fig. 4</xref>).</p>
      <p content-type="asset">
        <fig id="en_aop06511fig04-body3">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf04-en.jpg"/></fig>
      </p>
      <p>The analysis by 3D echocardiography showed medians and standard deviations of ventricular systolic and diastolic volumes of 252 &#177; 105 ml and 194 &#177; 86 ml, respectively, at baseline. After the CRT, there was no significant reduction in ventricular volumes, evaluated at 3D echocardiography. Three months after CRT, there was a reduction of 25 ml (10%) in average values of LVDV and 26 ml (13%) in average values of LVSV in relation to the baseline (LVDV: 227 &#177; 113 ml, p = 0.187; LVSV: 168 &#177; 95 ml, p = 0.065). At six months after CRT, the reduction of LVDV was 13 ml (5%) and 6 ml (6%) of the LVSV in relation to the baseline (LVDV: 239 + 129 ml, p = 0.163; LVSV: 183 + 115 ml, p = 0.347) (<xref ref-type="table" rid="en_aop06511tab02-body3">Table 2</xref>, <xref ref-type="fig" rid="en_aop06511fig02-body3">Fig. 2</xref> and <xref ref-type="fig" rid="en_aop06511fig03-body3">3</xref>). With respect to LVEF, there was an improvement (21.7%) compared to baseline values (LVEF: 0.23 &#177; 0.05), as shown at month three after CRT (LVEF: 0.28 &#177; 0.07, p = 0.008) and was maintained at month six (LVEF: 0.28 &#177; 0.10, p = 0.033) (<xref ref-type="table" rid="en_aop06511tab02-body3">Table 2</xref>, <xref ref-type="fig" rid="en_aop06511fig04-body3">Fig. 4</xref>).</p>
      <p>There was no change in left ventricular mass at month three (p = 0.511 by 3D echocardiography) and month six (p = 0.706 for 2D echocardiography, p = 0.479 on 3D echocardiography), after CRT (<xref ref-type="table" rid="en_aop06511tab02-body3">Table 2</xref>).</p>
      <p>At baseline, the correlation between methods was 0.96 for evaluation of LVDV, 0.95 for evaluation of LVSV, 0.87 for LVEF and 0.72 for LV mass. After six months of CRT, the correlation between 2D and 3D echocardiography for analysis of LVDV was 0.96, 0.95 for LVSV, 0.95 for LVEF and 0.77 for LV mass. After six months of CRT, the correlation between 2D and 3D echocardiography for analysis of LVDV was 0.98, 0.91 for LVSV, 0.96 for LVEF and 0.85 for LV mass.</p>
      <p>Regarding the evaluation of intra and interobserver variation on 3D echocardiography, the concordance correlation coefficient (CCC) of analysis of intraobserver LFDV was 0.95 (95% confidence interval: 0.80 to 0.99) and interobserver was 0.95 (95% confidence interval: 0.77 to 0.99). The CCC of intraobserver analysis of LVSV was 0.97 (95% confidence interval: 0.86 to 0.99) and interobserver was 0.95 (95% confidence interval: 0.81 to 0.99). The CCC of intraobserver LVEF analysis was 0.97 (95% confidence interval: 0.86 to 0.99) and interobserver was 0.92 (95% confidence interval: 0.71 to 0.98).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In patients with advanced HF, left ventricular dilation is considered an important independent predictor of worse prognosis<sup>11</sup>. Patients with idiopathic dilated cardiomyopathy and significant ventricular dilation have reduction of coronary flow reserve detected in myocardial perfusion imaging with nuclear medicine techniques and pharmacological stress echocardiography with dipiridamole<sup>12-14</sup>. These findings are associated with higher systolic stress and left ventricular wall in areas of abnormal oxygen consumption, suggesting the presence of ischemia and a worse prognosis in these patients.</p>
      <p>Therefore, patients with severe heart failure and significant ventricular dilation, as evidenced by increased LVDD and ventricular volumes, may have a poorer response to CRT because of lower coronary flow reserve and the presence of areas with abnormal pattern of oxygen consumption. The evaluation of the degree of ventricular dilation analyzed by 2D and 3D echocardiography at baseline provides important information about the evolution of patients after CRT. Thus, we know the importance of evaluating LVSV and LVDV before CRT.</p>
      <p>In a study by Anthony et al<sup>15</sup>, patients in the earliest stages of cardiomyopathy and minor alterations in ventricular geometry were more likely to respond to CRT. Additionally, the evaluation of volumetric changes after CRT provides important predictive information about the clinical outcomes in the natural evolution of the disease, as demonstrated originally by Yu et al<sup>16</sup> and confirmed in a recent study by Ypenburg et al<sup>17</sup>. Data regarding the use of pharmacological therapies stress the importance of left ventricular reverse remodeling in long-term prognosis, making thus this variable a very useful marker of clinical improvement. In the study by Ypenburg et al<sup>17</sup>, the extent of reverse remodeling also showed correlation with prognosis in the long term: the greater the rate of reverse remodeling, better the clinical evolution and vice versa.</p>
      <p>The value of three-dimensional echocardiography in the evaluation of ventricular volumes, ejection fraction and left ventricular mass has been proven in a number of studies with an excellent correlation of results compared to cardiac magnetic resonance imaging<sup>5,6</sup>. The acquisition of volumetric blocks, through 3D echocardiography, to evaluate these parameters, can be performed quickly, using an array transducer, and the quantification of data by a trained and experienced operator takes on average six to eight minutes<sup>18,19</sup>.</p>
      <p>Hence, 3D echocardiography is a very useful tool in echocardiography, increasing the accuracy of calculations of volumes, LVEF and left ventricular mass, without increasing significantly the duration of the test. However, currently, 3D echocardiography is not yet widely available; it requires specific equipment and computer programs for the quantification of data, and requires adequate training for the acquisition of volumetric blocks of good technical quality.</p>
      <p>
        <xref ref-type="fig" rid="en_aop06511fig05-body3">Figure 5</xref>
      </p>
      <p content-type="asset">
        <fig id="en_aop06511fig05-body3">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf05-en.jpg"/></fig>
      </p>
      <p>
        <xref ref-type="fig" rid="en_aop06511fig06-body3">Figure 6</xref>
      </p>
      <p content-type="asset">
        <fig id="en_aop06511fig06-body3">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf06-en.jpg"/></fig>
      </p>
      <p>
        <xref ref-type="fig" rid="en_aop06511fig07-body3">Figure 7</xref>
      </p>
      <p content-type="asset">
        <fig id="en_aop06511fig07-body3">
          <graphic xlink:href="1678-4170-abc-97-02-0111-00073-gf07-en.jpg"/></fig>
      </p>
      <p>Two-dimensional echocardiography, in turn, is widely available and has been the most widely used method for evaluation of patients about to undergo CRT and to evaluate the response after this therapy.</p>
      <p>This study compared the evaluation of data about the morphology and left ventricular function by 2D and 3D echocardiography, before CRT, which helps selecting candidates to CRT, three and six months after CRT, in order to assess response to treatment.</p>
      <p>The evaluation of ventricular volumes after CRT is important to recognize left ventricular reverse remodeling, defined as reduction of left ventricular diastolic and systolic volumes and improvement of LVEF. Identification of reverse remodeling by echocardiography has a prognostic importance, since the volumetric response has shown a better predictive value of uneventful survival and mortality when compared with the clinical response assessed by improvement in functional class (NYHA) and quality of life<sup>16,20</sup>. Once proven the superiority of 3D echocardiography, compared to 2D echocardiography, in the assessment of ventricular volumes, mass and LVEF, it is essential to assess the correlation between these two techniques, as the 2D echocardiography is the most widely used method in patients undergoing CRT.</p>
      <p>Ventricular volumes (LVDV and LVSV) assessed both by Simpson's method and by 3D echocardiography provide additional information on patient selection and response rate to CRT. The improvement and the degree of improvement in LVEF after CRT present good correlation with the improvement in clinical outcome of patients undergoing CRT. According to Di Biase et al<sup>21</sup>, an increase of six points or more in LVEF at three months after CRT presents a rate around 66% of event-free within five years of follow up.</p>
      <p>In this study, a significant improvement of LVEF measured by both methods (Simpson and 3D echocardiography) three months after CRT, which remained stable at six months of CRT in the total study sample. There was also an excellent correlation between methods for measuring left ventricular volume throughout the study, which demonstrates the usefulness of echocardiography in the monitoring and evaluation of reverse remodeling of patients undergoing CRT, while 3D echocardiography is not part of the echocardiography evaluation in daily clinical practice.</p>
      <p>Evaluation of LV mass by 3D echocardiography is superior to 2D echocardiography, as compared to RMC. It is important to note that despite the good correlation between 2D and 3D echocardiography for mass evaluation, Eco 3D is more accurate, justifying its use when available. However, despite the superiority of 3D echocardiography for evaluation of left ventricular volumes, mass and function over 2D echocardiography (compared to RMC, which is currently the standard method of reference for these analyses), 2D echocardiography is the most widely used method in clinical practice due to its availability and cost. Hence, the results of this study, demonstrating the excellent correlation between methods (2D and 3D echocardiography), makes 2D echocardiography a reliable method for evaluating reverse remodeling after CRT.</p>
      <p>
        <bold>Study limitations</bold>
      </p>
      <p>There was a slight increase in ventricular volume between three and six months after CRT, as detected by 3D echocardiography. We believe that this finding is still due to the limitations inherent in current technology of 3D echocardiography equipment. Patients included in this study had very high values of LVDD and significant dilation of ventricular volumes, making it difficult to include the entire left ventricle in the acquisition of three-dimensional block. Despite being excluded from the blocks with impossibility of evaluating two or more myocardial segments, the difficulty in assessing the sidewall on the coronal plane and inferior and anterior walls on the sagittal plane may have limited the calculation of left ventricular volumes on 3D echocardiography. Furthermore, limitations in the degree of opening of the ultrasonic beam and the low frame rate (20 to 30 volumes/second) of 3D echocardiography may have resulted in no significant difference between left ventricular volumes of GI and GII before the CRT.</p>
      <p>3D echocardiography, though available for about four decades, has not yet reached its final format and presents physical limitations and limitations in its format for presentation in various acquisition, reading and interpretation programs. The development of 3D echocardiography will undoubtedly enable working, in the near future, with patients with large ventricular dilatation with a marked variation in heart rhythm (atrial fibrillation) and respiratory rate.</p>
      <p>Another limitation is the non-use of cardiac MRI in the assessment of ventricular volumes and LVEF for comparison with 2D and 3D echocardiography, since this is the standard method of reference for this purpose.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>In this study, we observed a reduction of left ventricular diastolic and systolic volumes in addition to improvement in LVEF after CRT. There was an excellent correlation between the 2D and 3D echocardiography for evaluation of ventricular volumes and LVEF, and a good correlation between methods for evaluation of left ventricular mass before and after CRT.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by SOCESP from July 2009 to July 2010</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Viviane Tiemi Hotta from <italic>Faculdade de Medicina da USP</italic>.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
